Niemann-Pick Type C Disease: Protective Mechanisms from Neurodegeneration and Targets for Therapeutic Intervention. by Chung, Chan
  
Niemann-Pick Type C disease:  
protective mechanisms from  
neurodegeneration and  
targets for therapeutic intervention 
 
by 
 
Chan Chung 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Molecular and Cellular Pathology) 
in the University of Michigan 
2016 
 
 
 
 
 
Doctoral Committee:  
 
Professor Andrew P. Lieberman, Chair  
Associate Professor David B. Lombard 
Professor Jack M. Parent 
Assistant Professor Vikram G. Shakkottai 
Professor Joel A. Swanson 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©  Chan Chung 
2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
  
Dedication 
 
 
 This dissertation is dedicated to all Niemann-Pick disease patients and their families, 
especially the patient’s family who shared the progress of a disease in 2011 NPC conference. 
Whenever I was faced with an unexpected difficulty in my research, I remembered they were 
fighting a disease and I could get over a difficulty. 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
  
Acknowledgements 
 
 
Firstly, I would like to express my sincere gratitude to my mentor, Prof. Andy 
Lieberman, not only for the continuous support of my Ph.D. study but also for his patience and 
motivation. His guidance helped me in all the time of research and writing of this thesis. I could 
not have imagined having a better mentor for my Ph.D. study. In future, I wish to be a mentor 
like him. Also, due to his deep consideration, I could kill two birds (research and marriage). 
Besides my mentor, I would like to thank my thesis committee members: Prof. Jack 
Parent, Prof. David Lombard, Prof. Vikram Shakkottai, and Prof. Joel Swanson, for their 
insightful comments and encouragement as well as for deep questions which incented me to 
widen my research from various perspectives. Your expertise helped guide my growth as a 
scientist during my Ph.D. study. 
My sincere thanks also goes to Prof. Zaneta Nikolovska-Coleska, and Mrs. Laura Labut, 
for their kind assistance and support in the Department of Pathology. Especially, I thank Prof. 
Nicholas Lukacs, who is a former director of Molecular and Cellular Pathology graduate 
program. Without his tremendous advice and help, I could not survive from tight first-year Ph.D. 
coursework.  
I take this opportunity to express gratitude to all current and former labmates, Mark 
Schultz, Prasanth Puthanveetil, Kelsey Krus, Satya Reddy, Zhigang Yu, Varuna Banduseela, 
Kotaro Komori, Samir Nath, Ting Yu, Matthew Elrick, Brittany Dixon, and Elisa Giorgetti. 
Without their precious support, it would not be possible to conduct this research. In particular, I 
iv 
  
am grateful to Mark and Prasanth for scientific and non-scientific discussion to expand my 
intellectual horizon. I also appreciate Ting and Matt for showing me many new and valuable 
experimental methods. In addition, I would like to thank James Dell’Orco and Brian Gregorka. 
My completion of this project could not have been accomplished without their collaboration. 
To my caring, loving, and supportive wife, Boyoung: my deepest gratitude. When the 
times got rough, your encouragement was much appreciated. It was a great comfort and relief to 
know that you were willing to provide management of our household activities and to take care 
of me and our son while I completed my work. Owing to your unwavering love, patience and 
support, I could follow my interest as a scientist without worry. My heartfelt thanks. And, I thank 
my son, Sunwoo, for giving me the opportunity to be a father and the supreme happiness.  
Last but not the least, I would like to thank my family: my mother, parents-in-law, sister, 
brother-in-law, nieces, uncles and aunts for supporting me spiritually throughout writing this 
thesis and my life in general. Without their unceasing encouragement, support and attention, it 
would be impossible to keep studying what I longed for. And, I am sorry to my father and 
grandmother because I was not with them when they passed away.   
I am also grateful to my friends. In particular, I thank Geunyoung, who stuck by me 
during difficult times or good times. 
Finally, I am grateful to the God for the good health and well-being that were necessary 
to complete Ph.D. study. 
 
  
v 
  
Table of Contents 
 
Dedication ...................................................................................................................................... ii 
Acknowledgements ....................................................................................................................... iii  
List of Figures .............................................................................................................................. vii 
List of Tables ............................................................................................................................... viii 
List of Abbreviations ……………………………………………………………………………. ix 
Abstract ........................................................................................................................................ xii 
Chapter 
1. Introduction ................................................................................................................................ 1 
1.1 Niemann-Pick type C ....................................................................................................... 2 
1.2 Lysosomal proteases (cathepsins) .................................................................................... 5 
1.3 Lysosomal cell death ....................................................................................................... 9 
1.4 Selective neuronal survival ............................................................................................ 15 
1.5 Heat shock protein beta-1 (HSPB1) .............................................................................. 16 
1.6 Research objectives ....................................................................................................... 21 
2. Cystatin B, an endogenous inhibitor of lysosomal cathepsins, protects against Niemann-Pick C 
cerebellar degeneration ................................................................................................................. 22 
2.1 Abstract .......................................................................................................................... 22 
2.2 Introduction ................................................................................................................... 23 
2.3 Results ........................................................................................................................... 25
vi 
  
2.4 Discussion ...................................................................................................................... 43 
2.5 Materials and Methods .................................................................................................. 46 
2.6 Acknowledgements ....................................................................................................... 51 
3. Heat shock protein beta-1 modifies anterior to posterior Purkinje cell vulnerability in a mouse 
model of Niemann-Pick type C disease ........................................................................................ 52 
3.1 Abstract .......................................................................................................................... 52 
3.2 Introduction ................................................................................................................... 53 
3.3 Results ........................................................................................................................... 55 
3.4 Discussion ...................................................................................................................... 74 
3.5 Materials and Methods .................................................................................................. 76 
3.6 Acknowledgements ....................................................................................................... 83 
4. Conclusion ................................................................................................................................ 84 
4.1 Genetic interaction of NPC1 deficiency with cystatin B deletion .................................. 85 
4.2 Therapeutic strategies .................................................................................................... 91 
4.3 Identification of genes that modify neuronal survival and death in NPC1 deficiency ... 92 
4.4 Concluding remarks ....................................................................................................... 96 
References .................................................................................................................................... 97 
 
 
 
 
vii 
  
List of Figures 
 
Figure 
1.1 Model of NPC1/NPC2 function and NPC1 structure ……………………..…………………. 4 
1.2 Cathepsin B maturation ………………………………………………………………………. 8 
1.3 LMP-dependent apoptosis ………………………………………..………………………… 14 
2.1 Cystatin B knockdown increases cathepsin B activity in NPC1 patient fibroblasts………… 27 
2.2 Phenotype of Npc1, Cstb null mice.…………………………………………………………. 31 
2.3 The cerebellum of Npc1, Cstb null mice is markedly gliotic and atrophic………………….. 32 
2.4 Enhanced Purkinje cell loss following cystatin B deficiency is cell autonomous…………... 35 
2.5 Purkinje cell loss following cystatin B deficiency is due to neurodegeneration and not a 
neurodevelopmental deficiency…………………………………………………………………. 36 
2.6 Cathepsin mislocalization in Npc1 deficient Purkinje cells…………………………………. 40 
2.7 NPC1 deficient cells are more sensitive to oxidative damage and rescued by cathepsin B 
inhibition………………………………………………………………………………….…….. 42 
2.8 Model of cerebellar neurodegeneration in NPC1 disease…………………………………… 45 
3.1 Schematic of gene expression analysis……………………………………………………… 58 
3.2 Genes selectively expressed in posterior lobules of the cerebellar midline………………… 60 
3.3 Candidate neuroprotective or pro-degenerative genes……………………………………..…61 
3.4 HSPB1 promotes survival in cellular models of NPC1 disease…………………………….. 64 
3.5 HSPB1 over-expression rescues motor impairment and Purkinje cell loss…………………. 67 
3.6 HSPB1 over-expression does not rescue accumulation of ubiquitinated proteins or unesterified 
cholesterol……………………………………………………………………………………......68 
3.7 PKC and phosphorylated HSPB1 are co-expressed in Purkinje cells in posterior lobules….70 
3.8 Hspb1 knockdown exacerbates Purkinje cell loss…………………………………………….73 
 
 
viii 
  
List of Tables 
 
Table 
2.1 Expected and observed genotype ratios for pups …………………………………………… 28 
3.1 Genes differentially expressed in Purkinje cells in anterior or posterior lobules …………… 59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
  
List of Abbreviations 
 
17-allylamino-17-demethoxygeldanamycin (17-AAG) 
1-methyl-4-phenylpyridinium (MPP) 
4',6-diamidino-2-phenylindole (DAPI) 
Acid sphingomyelinase (ASM) 
Adeno-associated virus serotype 2 (AAV2) 
Adenosine triphosphate (ATP) 
Apoptotic protease-activating factor (Apaf-1) 
Ask1 (apoptosis signal regulated kinase 1) 
Avidin-Biotin Complex (ABC) 
Bis (monoacylglycero) phosphate (BMP) 
Bovine serum albumin (BSA) 
CA-074 methyl ester (CA-074ME) 
CNS (Central nervous system) 
Cystatin B (CSTB) 
Daxx (Death-Domain Associated Protein) 
Deoxyribonucleic acid (DNA) 
Diacylglycerol (DAG) 
Dimethyl sulfoxide (DMSO) 
Endoplasmic reticulum (ER) 
Feline immunodeficiency virus (FIV) 
Fetal bovine serum (FBS) 
Gene ontology (GO) 
GFAP (Glial fibrillary acidic protein) 
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) 
Green fluorescent protein (GFP)
x 
  
Heat shock protein 70 (HSP70) 
Heat shock protein 90 (HSP90) 
Heat shock protein beta-1 (HSPB1) 
Heat shock proteins (HSPs) 
Hemagglutinin (HA) 
Inositol-1, 4, 5-trisphosphate (IP3) 
Ionized calcium-binding adapter molecule 1 (IBA1) 
LAMP-1 (Lysosomal-associated membrane protein 1) 
LAPF (lysosome-associated and apoptosis-inducing protein containing PH and FYVE domains) 
Late endosomes (LE) 
Late endosomes and lysosomes (LE/Lys) 
Lethal concentration 50 (LC50) 
Low density lipoprotein (LDL) 
Lysosomal membrane permeabilization (LMP) 
Lysosomes (LY) 
Mannose-6-phosphate receptors (MPR) 
Mitogen-activated protein kinase-activated protein kinase-2 and 3 (MAPKAPK2/3) 
Mitogen-activated protein kinases (MAPK) 
Nerve growth factor (NGF) 
Niemann-Pick type A (NPA) 
Niemann-Pick type B (NPB) 
Niemann-Pick type C (NPC) 
Niemann-Pick type C1 disease (NPC1 disease) 
Non-targeted (NT) 
Optimal Cutting Temperature (OCT) 
Phosphate-buffered saline (PBS) 
Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-kinase) 
Phosphatidylinositol-specific phospholipase C, X domain containing 2 (PLCXD2) 
Phospholipase C (PLC) 
Protein kinase C, delta (PKC) 
xi 
  
Protein kinase D (PKD) 
Radioimmunoprecipitation assay buffer (RIPA buffer) 
Reactive oxygen species (ROS) 
Recombinant heat shock protein 70 (rHSP70) 
Rough endoplasmic reticulum (RER) 
Short hairpin RNA (shRNA) 
Significance Analysis of Microarrays (SAM) 
Small interfering RNA (siRNA) 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Sphingosine 1-phosphate phosphatase 2 (Sgpp2) 
Standard deviation (SD) 
Standard error of the mean (SEM) 
Superoxide dismutase 2 (SOD2) 
Trans-Golgi network (TGN) 
Tumor necrosis factor (TNF) 
Urokinase-type plasminogen activator (uPAR) 
Wild type (WT) 
 
 
 
 
 
 
 
 
xii 
  
Abstract 
 
Niemann-Pick type C (NPC) disease is a lysosomal storage disorder that causes 
progressive neurodegeneration and early death, often in children. The two disease-causing 
proteins, NPC1 and NPC2, are involved in the movement of unesterified cholesterol out of late 
endosomes and lysosomes (LE/Lys). Loss-of-function mutations in the NPC1 or NPC2 genes 
lead to the accumulation of unesterified cholesterol and glycosphingolipids in LE/Lys. NPC 
disease is characterized by severe neurological symptoms including ataxia, cognitive decline, 
seizures, dystonia, and vertical gaze palsy. The mechanism underlying this neurodegeneration 
has not been identified, and there is no effective treatment for the disease. This dissertation aims 
to characterize a pathway leading to neuronal death and several modifier genes that promote 
neuronal survival in NPC disease. This work may provide a foundation for future studies that 
could lead to the development of novel therapies.  
Chapter 1 introduces the genetics and pathology of NPC disease, and reviews lysosomal 
proteases and heat shock protein beta-1 (HSPB1). After reviewing the known factors involved in 
NPC disease, chapter 2 presents studies demonstrating that cystatin B (CSTB), an endogenous 
inhibitor of cathepsins B, H, and L, protects Purkinje cells against cerebellar degeneration in a 
mouse model of NPC disease. To accomplish this, the effect of CSTB deficiency on cathepsin 
activity in NPC patient fibroblasts is shown first. Next, the neuropathology is investigated in 
Cstb null mice that are also deficient in Npc1 globally or specifically within Purkinje cells. These 
data demonstrate a marked exacerbation of neuron loss in double mutant mice. In addition, 
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analyses demonstrate that lysosomal membrane permeabilization induces leakage of lysosomal 
contents, leading to apoptosis in Purkinje cells in the diseased cerebellum.  
Chapter 3 presents research that seeks to identify genes that may be neuroprotective or 
create vulnerability in the NPC brain, using the Allen Brain Atlas. One candidate gene, HSPB1, 
is confirmed to promote neuronal survival in cellular models of NPC disease, and the mechanism 
by which HSPB1 protects cells from NPC deficiency is shown. Studies also determine the effect 
of HSPB1 over-expression on an NPC mouse model by conducting behavioral and histological 
examinations. In addition, phosphorylation of HSPB1 is found to be tightly associated with 
Purkinje cell rescue. The modulatory effect of Hspb1 on neurodegeneration in vivo is confirmed 
using Hspb1 knockdown. Finally, chapter 4 summarizes these findings, discusses relevant 
questions that remain open, and suggests future directions for work in this area. The work 
described in this thesis will help us understand the pathways leading to neurodegeneration in 
NPC disease. It is my hope that this knowledge will enable the identification of targets for the 
future development of disease modifying therapies. 
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Chapter 1 
 
 
Introduction 
 
Niemann-Pick disease is a group of inherited lysosomal disorders that is characterized by 
defects in intracellular lipid trafficking. As a result, patients’ lipid metabolism— which 
encompasses the breakdown, transport, and use of fats and cholesterol in the body—is abnormal. 
Niemann-Pick disease causes an accumulation of harmful amounts of lipids in the spleen, liver, 
lungs, bone marrow, and brain. It is divided into three main types: A, B, and C.  
Niemann-Pick types A and B (NPA and NPB) are caused by loss of function mutations in 
the gene encoding acid sphingomyelinase (ASM), the enzyme which converts sphingomyelin 
into ceramide in lysosomes. A deficiency in ASM causes an accumulation of sphingomyelin in 
lysosomes, resulting in cell death and the malfunction of major organ systems, eventually 
leading to early death. Although both NPA and NPB are caused by ASM deficiency, the clinical 
symptoms in affected patients are remarkably different. NPA patients produce little or no ASM, 
causing abdominal swelling and severe neurologic disease that leads to death, usually by 2 to 4 
years of age. In contrast, NPB patients produce approximately 10% of the normal amount of 
ASM, which leads to almost no nervous system involvement. They survive into adulthood with 
health complications, including enlarged livers and spleens and respiratory problems. The 
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enlargement of organs and repeated respiratory infections can cause cardiovascular stress and 
lead to heart disease (Schuchman and Wasserstein, 2015). 
Niemann-Pick type C (NPC) is caused by loss of function mutations in a pair of proteins 
called NPC1 (Carstea et al., 1997) and NPC2 (Naureckiene et al., 2000). These proteins appear 
to be essential for the movement of unesterified cholesterol out of late endosomes and lysosomes 
(LE/Lys). A deficiency of either of these proteins causes cholesterol and sphingolipid 
accumulation in LE/Lys. Ninety-five percent of NPC patients have mutations in the gene 
encoding NPC1 (Patterson et al., 2012). NPC disease is characterized by ataxia, cognitive 
decline, seizures, dystonia, vertical gaze palsy and early mortality (Pacheco and Lieberman, 
2008). A few available drugs provide symptomatic relief but do not alter the course of the 
disease.  
 
1.1 Niemann-Pick type C  
NPC disease is an autosomal recessive neurodegenerative disorder with an estimated 
minimum incidence of 1 per 120 000 live births (Vanier, 2010). Loss of function mutations in 
NPC1 or NPC2 produce a similar biochemical phenotype characterized by the accumulation of 
unesterified cholesterol in LE/Lys; these lipids are derived from internalized low density 
lipoprotein (LDL) particles. Under normal conditions, LDL particles are internalized by cell 
surface receptors and hydrolyzed into unesterified cholesterol in the endocytic compartment. The 
unesterified cholesterol is then transported to the cell surface or to the endoplasmic reticulum, 
the site of cholesterol esterification. Both NPC1 and NPC2 are involved in the movement of 
unesterified cholesterol out of LE/Lys. 
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1.1.1 Genetics 
The NPC1 protein is localized to the limiting membranes of LE/Lys and is a large 
multipass glycoprotein comprising 1278 amino acids. It consists of 13 transmembrane domains, 
three large lumenal loops (amino acids 25–264, 370–621, and 854–1098), a sterol-sensing 
domain (amino acids 616–797), and a cytoplasmic C-terminal lysosomal targeting motif (Davies 
and Ioannou, 2000). The first N-terminal lumenal loop forms a hydrophobic pocket containing a 
cholesterol binding site (Kwon et al., 2009). The second lumenal loop binds to the NPC2 protein 
(Deffieu and Pfeffer, 2011), while the third lumenal domain is known as a cysteine-rich loop. 
Interestingly, approximately one-third of all identified human mutations are located in this loop 
(Park et al., 2003). The C-terminal tail of NPC1 interacts with the clathrin adaptor AP-1 via a 
dileucine motif. This interaction appears to be important in the targeting and functioning of 
LE/Lys (Poirier et al., 2013). The sterol-sensing domain is located between the third and seventh 
transmembrane domains (Davies and Ioannou, 2000). It must function properly for NPC1 to bind 
to cholesterol (Ohgami et al., 2004) and for cholesterol homeostasis to occur (Figure 1.1) 
(Millard et al., 2005). 
NPC2 is a small soluble glycoprotein comprising 151 amino acids. It is located within 
lysosomes, binding to cholesterol with high affinity in a 1:1 molar ratio (Xu et al., 2007) and 
facilitating the rapid transfer of cholesterol—but not glycosphingolipids, oleic or palmitic acids, 
or cholesterol oleate—between liposomes or membranes in vitro. In an acidic environment, 
cholesterol is rapidly transferred from NPC2 into membranes containing a bis (monoacylglycero) 
phosphate (BMP) or an anionic phospholipid (Cheruku et al., 2006). Without NPC2, NPC1 can 
transfer cholesterol to liposomes bidirectionally but very slowly (Infante et al., 2008; Kwon et 
al., 2009). Unesterified cholesterol binds to the hydrophobic pocket of NPC2, which is 
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sandwiched between the two β-sheets of NPC2 (Friedland et al., 2003). The binding of NPC2 to 
cholesterol reaches NPC1 in the limiting membrane and transfers cholesterol from its 3ß-
hydroxyl moiety through a hand-off mechanism. During this process, it is likely that NPC2 binds 
transiently to NPC1 (Figure 1.1) (Deffieu and Pfeffer, 2011).  
 
Figure 1.1 Model of NPC1/NPC2 function and NPC1 structure 
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1.1.2 Clinical presentation 
Because NPC1 and NPC2 are involved in the movement of unesterified cholesterol out of 
LE/Lys, a defect in either of the two proteins will lead to a progressive accumulation of 
unesterified cholesterol in the endolysosomal compartment. As noted above, approximately 95 % 
of NPC patients have NPC1 mutations, and the remaining patients have NPC2 mutations. 
Although Niemann-Pick type C1 disease (NPC1 disease) and NPC2 disease have different 
genetic causes, the signs and symptoms are very similar. Disease caused by NPC1 and NPC2 
deficiency usually becomes apparent in childhood, although signs and symptoms can develop 
any time from early infancy to adulthood. Patients usually have difficulty coordinating 
movements (ataxia), an inability to move their eyes vertically (vertical supranuclear gaze palsy), 
abnormal muscle tone (dystonia), enlarged spleens and livers, and interstitial lung disease. 
Patients also have problems with speech and swallowing that worsen over time, eventually 
interfering with feeding. Affected individuals often experience progressive decline in intellectual 
function and about one-third have seizures. A child who shows symptoms before age 1 may not 
live to school age. Those who show symptoms after entering school may live into their mid- to 
late teens. Some patients may live into their 20s and beyond. Although research has progressed 
since the gene was discovered in 1997, only one FDA-approved drug (miglustat) exists for the 
treatment of NPC1 and NPC2. It provides mild symptomatic reduction but does not alter the 
course of the disease. 
 
1.2 Lysosomal proteases (cathepsins) 
The lysosome is a critical organelle involved in NPC pathogenesis. It is a bilayer-
membrane-limited organelle that contains several hydrolytic enzymes in an acidic lumen 
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(Settembre et al., 2013). More than 50 diseases related to lysosome dysfunction have been 
reported since Christian de Duve discovered the lysosome in 1955 (De Duve et al., 1955; Schultz 
et al., 2011). Lysosome means digestive body in Greek, and, as the name implies, lysosomes are 
the main digestive organelles in eukaryotic cells. Lysosomes degrade intracellular and 
extracellular macromolecules within their lumina. Intracellular molecules are targeted for 
lysosomal degradation through autophagy, while extracellular cargo is delivered to the lysosome 
by endocytosis or phagocytosis (de Duve, 2005). In order to efficiently degrade biological 
macromolecules, lysosomes contain 50 soluble acidic hydrolases, including proteases, lipases, 
nucleases, glycosidases, phospholipases, phosphatases, and sulfatases (Bainton, 1981; Journet et 
al., 2002). Among the lysosomal hydrolases, of particular importance are lysosomal proteases 
called cathepsins. Cathepsins are classified by their catalytic mechanism: aspartic, serine, 
threonine, metallo, and cysteine (Pislar and Kos, 2014). Eleven human cysteine cathepsins (B, C, 
F, H, L, K, O, S, V, W, X/Z) constitute the largest cathepsin family. All cysteine cathepsins were 
identified in the human genome and characterized by molecular function and structure (Turk et 
al., 2012).  
Among cysteine cathepsins, cathepsin B is the most abundant lysosomal protease. It 
performs a housekeeping function required for protein turnover, digesting cell proteins, 
chromatin, complex carbohydrates, and lipids. Cathepsin B is synthesized as a zymogen, which 
is an inactive enzyme precursor, and is processed to the mature form by autocatalysis or by the 
action of other proteases. Preprocathepsin B, which consists of 17 amino acids in the pre-part, 62 
amino acids in the pro-part, and 252 amino acids in the mature part, is synthesized on the rough 
endoplasmic reticulum (RER) (Kirschke et al., 1995; Mort and Buttle, 1997). Preprocathepsin B 
is translocated into the lumen of the RER by the 17 amino acids in the pre-part, which is also 
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called the signal peptide. Procathepsin B, an inactive 43/46 kDa precursor form, is formed by 
removal of the signal peptide and is glycosylated at two asparagine residues with high-mannose 
glycans in the RER lumen. Procathepsin B is then transported to the Golgi apparatus, and 
processed by modification of mannose residues to mannose-6-phosphate. The phosphorylated 
protein binds to mannose-6-phosphate receptors (MPR) in the trans-Golgi network (TGN) and is 
transported to lysosomes via transport vesicles. In an acidic environment, procathepsin B can 
undergo autocatalytic activation as a result of proteolytic cleavage and dissociation of the 
propeptide. The removal of the propeptide generates a 31 kDa mature single chain form of 
cathepsin B. A proteolytic cleavage between residues 47 and 50 and the excision of the dipeptide 
generates the double chain form, comprising a heavy chain of 25 kDa and a light chain of 5 kDa 
(Figure 1.2) (Frosch et al., 1999; Kirschke et al., 1995; Mort and Buttle, 1997). Alternatively, 
cathepsin B can be activated by cathepsin D (van der Stappen et al., 1996) and cathepsin G, 
urokinase-type plasminogen activator (uPAR), tissue-type plasminogen activator, and elastase 
(Dalet-Fumeron et al., 1996; Dalet-Fumeron et al., 1993). Structurally, cathepsin B is a bilobal 
protein, generating the active site of the enzyme at the interface between the two lobes (Musil et 
al., 1991). Cathepsin B can function as an endopeptidase and an exopeptidase (Keppler and 
Sloane, 1996; Musil et al., 1991). This dual activity is caused by an occluding loop that disturbs 
the access of substrates to the active site (Illy et al., 1997). In the acidic environment of 
lysosomes, the occluding loop partially blocks and prevents large substrates from gaining access 
to the active site but allows access of synthetic substrates or the C-terminus of proteins. Thus, 
cathepsin B has carboxydipeptidase activity in an acidic environment. At neutral pH, the 
occluding loop of cathepsin B is moved from active site, which allows large substrates to bind to 
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the active site. This model explains how cathepsin B can function as an endopeptidase as well as 
an exopeptidase (Illy et al., 1997; Quraishi et al., 1999). 
 
 
Figure 1.2 Cathepsin B maturation 
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1.3 Lysosomal cell death 
Christian de Duve used the term “recycling bin” to describe the function of lysosomes. 
Also, because of the acid hydrolases in lysosomes, he defined them as “suicide bags” (de Duve, 
1983). Three major pathways regulate cell death: necrotic, autophagic, and apoptotic (Galluzzi et 
al., 2007). The results of many studies have shown that lysosomes can be involved in each of 
these cell death pathways.  
Necrosis is largely triggered when cell damage is too severe and catastrophic to control. 
Because lysosomes contain catabolic enzymes, their rupture can be potentially harmful to the 
cell. The release of lysosomal contents can trigger a cascade of hydrolysis in the cytoplasm and 
generalize cytoplasmic acidification with potentially lethal consequences for the cell. However, 
increasing evidence suggests that even the necrotic process may be tightly regulated. Cytosolic 
calcium concentration in neurons was demonstrated to increase during necrosis, leading to an 
imbalance of proteolysis and, in particular, activation of calpains and aspartic cathepsins due to 
lysosomal membrane permeabilization (LMP) (Syntichaki et al., 2002). Moreover, later studies 
reported that calpain-mediated LMP was essential in hypotonic shock, heat shock, oxidative 
stress, hypoxia, and cation channel hyperactivity, with cysteine cathepsins found to be the major 
downstream regulators (Luke et al., 2007). While a few key components of the necrotic cell 
death pathway have been identified, the molecular mechanisms of necrosis are much less clear 
than those of apoptosis and autophagy. It is likely that necrosis results from the interplay of 
several signaling pathways, such as mitochondrial dysfunction, reactive oxygen species (ROS), 
ATP depletion, calpain- and cathepsin-mediated proteolysis, and early plasma membrane 
rupture (Golstein and Kroemer, 2007). 
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A second cell death pathway is autophagic cell death, also called type II programmed cell 
death. It is characterized by the large-scale accumulation of autophagosomes (Levine and 
Kroemer, 2008). Autophagy is the main process for degrading and recycling cellular components 
(Kobayashi, 2015). During autophagy, double membrane autophagosomes are packed with cargo 
that is delivered to lysosomes. Autolysosomes, which are the fusion products of autophagosomes 
and lysosomes, break down this cargo using lysosomal hydrolases. This pathway helps maintain 
the cellular energy level during starvation. Similarly, the removal of damaged organelles 
provides nutrients to the cell and promotes survival. Through this mechanism, autophagy 
protects the organism from various stressors and pathologies and is essential for maintaining 
homeostasis (Levine and Kroemer, 2008; Mizushima et al., 2008). However, under certain 
conditions, autophagy is detrimental to the cell. For example, at the end of Drosophila larval 
development, larval midgut and salivary gland cells display apoptotic phenotypes including 
DNA fragmentation and increased proapoptotic genes. In addition, these cells show numerous 
autophagosomes and increased expression of autophagic genes, as assessed by elevated levels of 
Atg mRNAs (Denton et al., 2009; Jiang et al., 1997; Lee et al., 2002; Li and White, 2003). This 
cell death is delayed by autophagy blockage (Berry and Baehrecke, 2007; Denton et al., 2009). 
Also, in a mammalian cell line, autophagic genes are required for cell death that occurs in a 
caspase-independent manner (Shimizu et al., 2004; Yu et al., 2004). Cells undergoing autophagic 
cell death initially show degradation of cytoplasmic components by the autophagic process, and 
this precedes nuclear collapse (Bursch, 2001). Notably, however; no study has shown this 
pathway to trigger cell death in a mammalian animal model. Therefore, the importance of 
autophagic cell death in mammalian systems is open to debate. It is conceivable that constitutive 
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autophagy could eventually destroy a cell, and that some proteins that are essential for autophagy 
could participate in signaling pathways that lead to cell death (Tsujimoto and Shimizu, 2005). 
A third cell death pathway is apoptosis. This pathway is characterized morphologically 
by the production of apoptotic bodies. These remnants of dead cells are engulfed and removed by 
phagocytic cells before they induce damage to surrounding cells. Apoptosis plays an especially 
important role in development and homeostasis. A molecularly critical step in apoptosis is 
caspase activation, which can be initiated in several ways: by death receptors, apoptosomes, and 
granzymes. A number of apoptotic proteins target mitochondria, which are the central organelles 
in this cell death pathway (Danial and Korsmeyer, 2004; Krenn et al., 2015). These proteins 
cause the formation of membrane pores or increase the membrane permeability of mitochondria, 
leading to the leakage of apoptotic effectors. It has also been suggested that lysosomes and 
lysosomal cathepsins play a role in apoptosis, including in neurodegeneration and aging, 
mediated primarily by oxidative stress (Kurz et al., 2008b; Leist and Jaattela, 2001; Turk et al., 
2002; Wei et al., 2008). Lysosomes can be damaged by free radicals. Following treatment with 
hydrogen peroxide, which easily crosses membranes and catalyzes Fenton reactions with 
lysosomal iron, free radicals destabilize the lysosomal membrane and induce LMP-dependent 
cell death. The iron chelator, deferoxamine, inhibits oxidant-induced lysosomal damage. Studies 
on this topic strongly support the role of Fenton chemistry in oxidant-induced LMP (Krenn et al., 
2015; Terman et al., 2006; Zhao et al., 2003). In addition to direct effects of lysosomal ROS in 
LMP, cathepsin B released into cytosol can enhance ROS formation in mitochondria and activate 
phospholipase A2, which is capable of inducing LMP, thereby creating a positive feedback loop 
(Zhao et al., 2003). Also, LMP has been shown to trigger a cascade of regulated cell demise 
mediated by the release of lysosomal enzymes into the cytosol, which induces cell death. 
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1.3.1 LMP-dependent apoptosis 
Accumulating evidence suggests that the release of cathepsins into the cytoplasm triggers 
lysosomal cell death in either a mitochondrion-independent manner or a mitochodrion-dependent 
manner (Groth-Pedersen and Jaattela, 2013). Because caspases are activated in the cytosol during 
apoptosis, it is logical that lysosomal proteases would redistribute to the cytosol during LMP-
dependent apoptosis. However, massive rupture of lysosomes has been show to lead to necrosis 
(Figure 1.3) (Bursch, 2001). To induce apoptosis without necrosis, small-scale lysosomal 
leakage and relocation of lysosomal proteases to the cytosol are thought to be required. It was 
reported that active lysosomal proteases and their precursor forms traffic within different 
organelles and across lysosomal membranes spontaneously (Berg et al., 1995; Claus et al., 1998). 
Also, cathepsins are synthesized as inactive precursors and activated by cleavage in the acidic 
environment of the lysosome (Katunuma, 2010). Therefore, in the past, it was assumed that 
lysosomal cysteine proteases were extremely unstable and rapidly inactivated at neutral pH. 
However, a number of studies have reported that cysteine cathepsins are stable, maintaining 
activity at neutral pH such as that which is found in the cytoplasm (Turk et al., 1995; Turk et al., 
1993; Turk et al., 1994). In vitro experiments performed at neutral pH showed that the cathepsins 
B, H, L, S, and K cleave Bid predominantly at Arg residues 65 or 71 and trigger the release of 
cytochrome c from isolated mitochondria (Cirman et al., 2004). Released cytochrome c builds 
apoptosomes with apoptotic protease-activating factor (Apaf-1) and activates capase-9. Activated 
caspase-9 induces the activation of caspase-3, 6, and -7, leading to cell death (Figure 1.3) 
(Taylor et al., 2008). In addition, cathepsin B, under certain conditions, has been shown to 
increase caspase-3 activity in brain cells (Yakovlev et al., 2008).  
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Many studies have reported that tumor necrosis factor (TNF) induces LMP. This has been 
demonstrated by staining lysosomal components or by tracking a loaded dextran into lysosomes 
through endocytosis (Gyrd-Hansen et al., 2006; Li et al., 2007; Werneburg et al., 2004; 
Werneburg et al., 2002). In a mouse model, caspase-9, which is essential for TNF-induced cell 
death, was cleaved and activated directly by caspase-8, allowing for mitochondrion-independent 
LMP induction (Varfolomeev et al., 1998). In human cancer cells, TNF-induced LMP depends 
on mitochondrial outer membrane permeabilization, cytochrome c release, and apoptosome-
mediated activation of caspase-9 rather than caspase-8 (Figure 1.3) (Foghsgaard et al., 2001; 
Gyrd-Hansen et al., 2006). These studies suggest that caspase-9 may function as a more general 
link between the intrinsic apoptosis pathway and LMP. Also, TNF can induce an increase in 
ROS, leading to caspase-independent cell death (Jaattela and Tschopp, 2003). Other LMP 
inducers—bortezomib, omeprazole, norfloxacin, and siramesine—promote the production of 
ROS as well (Boya et al., 2003; De Milito et al., 2007; Ostenfeld et al., 2005; Yeung et al., 
2006). It is also known that ROS or photo-oxidation triggers LMP (Caruso et al., 2004; Ollinger 
and Brunk, 1995) and that ROS initiates cell death in many pathways (Orrenius, 2007; Raj et al., 
2011; Valencia and Moran, 2004). In chapter 2, I will test whether LMP and cathepsin leakage 
contribute to the neurodegeneration of Purkinje cells in the Niemann-Pick C brain. 
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Figure 1.3 LMP-dependent apoptosis 
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1.4 Selective neuronal survival 
Many inherited neurodegenerative diseases affect only select populations of neurons, 
despite the fact that the mutant or aggregated protein is widely present throughout the nervous 
system (Double et al., 2010). For example, Parkinson’s disease shows severe loss of pigmented 
neurons in the pars compacta of the substantia nigra although alpha-synuclein is expressed in 
most brain regions (Sulzer and Surmeier, 2013). Similarly, selective neuronal vulnerability 
characterizes many of the age-dependent protein aggregation disorders, including Alzheimer’s 
disease (Mann, 1996), amyotrophic lateral sclerosis and the  polyglutamine expansion disorders 
(Byers et al., 1973). It remains unclear why specific brain regions are vulnerable in different 
neurodegenerative diseases, and how some neurons in the regions of vulnerability survive 
despite progressive neurodegeneration. 
We study Purkinje cells as one example of selective neuronal vulnerability in the NPC 
brain. Correlated with loss of Purkinje cells are behavioral deficits, including ataxia and 
abnormalities of posture and gait (Mullen et al., 1976). Although Purkinje cells are uniform 
morphologically and electrophysiologically, and similarly express the NPC1 and NPC2 proteins, 
the extent of Purkinje cell loss occurs in a  nonuniform manner across the cerebellum of NPC1 
and NPC2 deficient mice (Elrick et al., 2010; German et al., 2001; Marschalek et al., 2014). In 
the cerebellar midline, Purkinje neurons in lobule X are strongly resistant to loss of NPC1 or 
NPC2. In contrast, neurons in the anterior zone (lobules II-V) show severe degeneration, while 
neurons in the intermediate (lobules VI-VII) and posterior zones (lobule VIII and rostral aspect 
of lobule IX) are moderately susceptible to degeneration (Elrick et al., 2010; German et al., 
2001; Marschalek et al., 2014). Interestingly, a similar distinct spatiotemporal pattern of loss is 
reproducible across many unrelated diseases and injuries (Clark et al., 1997; Sarna et al., 2001; 
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Sleat et al., 2004; Takahashi et al., 1998; Tavani et al., 2003; Yoneshige et al., 2010). As a 
similar pattern of Purkinje cell death results from a variety of genetic and environmental injuries, 
we hypothesize that the selective vulnerability of Purkinje cell subpopulations arises not from the 
initiating event of the disease process, but rather from the differential activation of cell death 
pathways in response to the disease. To test this hypothesis, in chapter 3, I will identify and test 
genes that protect Purkinje neurons from the toxicity of NPC disease using a bioinformatics 
approach. Among the potential genetic regulators of Purkinje cell vulnerability that I identify is a 
small heat shock protein known as heat shock protein beta-1 (HSPB1). 
 
1.5 Heat shock protein beta-1 (HSPB1)  
It was reported in 1974 that a few proteins are synthesized after subjecting Drosophila 
salivary glands to heat shock (Tissieres et al., 1974). This study initiated the discovery of a 
universal protective mechanism to preserve cellular function and homeostasis from not only 
hyperthermia but also from different types of environmental stress such as toxins, ROS, 
starvation, and viral infection (Lindquist, 1986; Santoro, 2000). This mechanism involves the 
rapid induction of a specific set of genes encoding cytoprotective proteins: heat shock proteins 
(HSPs) (Lindquist and Craig, 1988; Morimoto and Santoro, 1998). Despite the name, HSPs can 
be activated under non-stressful conditions such as those that occur during progression through 
the cell cycle, development, and differentiation. (Hang et al., 1995; Jerome et al., 1993; Milarski 
and Morimoto, 1986; Sistonen et al., 1992; Yang et al., 2006). HSPs are divided into different 
families, based on molecular size: hsp100, hsp90, hsp70, hsp60, hsp40, and small HSPs. In 
mammalian cells, several HSPs function as molecular chaperones, enabling proteins to attain a 
native confirmation, promoting the clearance of terminally misfolded proteins, and assembling or 
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disassembling macromolecular structures. Under conditions of stress, protein aggregation is 
increased, eventually leading to cell and tissue death. One function of HSPs is to hold misfolded 
proteins in an intermediate folded state before the protein enters into a competent refolded state. 
During the intermediate state, HSPs function as kinetic traps to prevent formation of aggregates 
(Morimoto and Santoro, 1998). Another function of HSPs under stress is to increase cellular 
viability in various ways, such as lysosomal membrane stabilization, survival gene induction, 
and apoptotic gene inhibition (Enomoto et al., 2013; Nylandsted et al., 2000; Nylandsted et al., 
2004). 
HSPB1 is one of the small heat shock proteins. It is also called HSP27 in humans and 
HSP25 in mice. HSPB1 functions as a chaperone, and acts to prevent the formation of aggregates 
of polypeptides or misfolded or unfolded proteins. HSPB1 has been shown to act in multiple 
cellular pathways, including the stabilization of the cytoskeleton and as an anti-apoptotic and 
anti-oxidant protein, similar to other HSPs that act in response to stress or in non-stress 
conditions (Arrigo, 2007).  
HSPB1 resides mainly in the cytosol and acts as an ATP-independent chaperone (Lianos 
et al., 2015). The chaperone function of HPSB1 was first shown in a study in which murine 
Hspb1 and human HSPB1 prevented the aggregation of citrate synthase and α-
glucosidase (Jakob et al., 1993). Many studies have revealed that phosphorylation of HSPB1 
mediates its oligomerization state. HSPB1 forms homo-ologomers, ranging from dimers and 
tetramers (favored by phosphorylation) to multimers of up to 800 kDa (favored by 
dephosphorylation) (Arrigo and Gibert, 2012). Dephosphorylated large complexes of HSPB1 
have chaperone functions (Ehrnsperger et al., 2000; Jakob et al., 1993). In contrast, 
phosphorylated HSPB1 stabilizes the actin cytoskeleton (Huot et al., 1996; Lavoie et al., 1995). 
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HSPB1 also has potent anti-apoptotic properties and has been implicated in a number of 
additional disease pathways, having both protective and counter-protective capacities (Khalil et 
al., 2011). In an environment of chemical stress, HSPB1 performs anti-apoptotic functions by 
interacting with caspase-dependent and independent apoptosis steps. In the caspase-independent 
apoptosis pathway, HSPB1 binds to Daxx (death domain-associated protein 6) and prevents its 
interaction with Ask1 (apoptosis signal regulated kinase 1) and Fas (a cell death receptor), 
leading to inhibition of their proapoptotic activities (Charette and Landry, 2000). Additionally, 
HSPB1 inhibits Bax-mediated mitochondrial apoptosis by promoting Akt activation via a PI3-
kinase-dependent mechanism (Havasi et al., 2008). It has also been reported that HSPB1 
provides protection against programmed cell death by inhibiting caspase-dependent apoptosis at 
multiple levels, through the binding and sequestration of cytochrome c (Bruey et al., 2000) and 
caspase-3 (Pandey et al., 2000). Whether the phosphorylation state is required for most anti-
apoptotic activities is unknown. However, a clue can be found in one study, which demonstrated 
that phosphorylated HSPB1 is required to inhibit DAXX (Charette and Landry, 2000). Recently, 
phosphomimetic HSPB1 was shown to protect against apoptosis inducers such as Fas agonist 
antibodies, staurosporine, and cytochalasin D, while non-phosphorylatable HSPB1 gave no 
protection or only mild protection against apoptosis inducers. These data suggest that the anti-
apoptotic activities of HSPB1 are primarily attributable to the phosphorylated species (Paul et 
al., 2010). In contrast, large complexes of dephosphorylated HSPB1 have been shown to prevent 
oxidative damage (Preville et al., 1999). HSPB1 can also act to reduce the concentration of ROS 
by increasing intracellular glutathione levels and lowering intracellular iron concentration 
through downregulation of transferrin receptor 1-mediated iron uptake (Arrigo et al., 2005; Chen 
et al., 2006). 
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1.5.1 HSPB1 function in the brain 
Mutations or modifications in HSPB1 can lead to adverse pathological conditions due to 
(1) toxicity from misfolded or aggregated proteins whose clearance is impaired by diminished 
HSPB1 function, or (2) an inability to cope with stress as a result of loss of HSPB1 function. 
That the chaperone activity of HSPB1 can limit toxicity of misfolded or aggregated proteins is 
supported by data showing that overexpression of HSPB1 ameliorates neurodegeneration in 
models of Alzheimer disease (Shimura et al., 2004; Toth et al., 2013), Parkinson disease (Lee et 
al., 2012; Renkawek et al., 1999), and amyotrophic lateral sclerosis (Vleminckx et al., 2002). 
Moreover, a mutation in HSPB1 diminishes axonal transport in the peripheral nervous system 
(Almeida-Souza et al., 2011) and impairs neurofilament assembly (Ackerley et al., 2006). In 
addition, the HSPB1 mutant reduces acetylated α-tubulin in dorsal root ganglion cells, leading to 
reduced mitochondrial movement and dysfunction of the axon cytoskeleton and axonal 
transport (Irobi et al., 2004). 
HSPB1 also functions in the brain to provide neuroprotection against a variety of cellular 
stressors. Overexpression of HSPB1 protects dorsal root ganglia neurons from apoptosis induced 
by nerve growth factor withdrawal or exposure to retinoic acid (Wagstaff et al., 1999). Similarly, 
induced HSPB1 protects PC12 cells from MPP+ toxicity, leading to a decrease in caspase 
activity (Quigney et al., 2003). In vivo, HSPB1 transgenic mice showed reduced apoptosis 
induced by kainic acid injection into the hippocampus (Akbar et al., 2003). In addition, it was 
demonstrated that phosphorylation of HSPB1 reduced infarct size by diminishing neuronal cell 
death in HSPB1 transgenic mice (Stetler et al., 2012; van der Weerd et al., 2010).  
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The expression of HSPB1 in the mouse cerebellum characterizes a subset of Purkinje 
neurons. This heterogeneity of Purkinje neurons reflects the organization of the cerebellar cortex, 
which is divided into a series of transverse zones, with each zone subdivided into parasagittal 
stripes. The expression pattern of many molecules defines the parasagittal stripes and the 
transverse zones in greater detail. For example, the expression of zebrin II reveals an array 
of  transverse zones in the vermis and in both hemispheres (Marzban and Hawkes, 2011). 
An additional marker of Purkinje cell heterogeneity is HSPB1 (Kalesnykas et al., 2007; 
Plumier et al., 1997; Wilkinson and Pollard, 1993). A number of studies have shown that specific 
populations of Purkinje cells express HSPB1 in the transverse zones, and that these cells appear 
to be more resistant to neurodegeneration in a variety of model systems, including shaker rats 
(Tolbert et al., 1995), toppler mice (Duchala et al., 2004), and PrP null mice (Rossi et al., 2001). 
Interestingly, studies have demonstrated that various mouse models of Niemann-Pick disease, 
with loss of function mutations in the genes encoding acid sphingomyelinase, Npc1 or Npc2, 
display a similar pattern of Purkinje cell degeneration and resistance (Sarna et al., 2001; Sarna et 
al., 2003). In all of these mice, the surviving Purkinje cells are in the same transverse zone as 
HSPB1. These cells are also aligned in parasagittal stripes in the central zone and the nodular 
zone, and along the border of the posterolateral crescent in the paraflocculus/flocculus, directly 
corresponding to the expression pattern that occurs using HSPB1 immunohistochemistry 
(Armstrong et al., 2000). In chapter 3, I will provide evidence that HSPB1 is neuroprotective 
against NPC1 deficiency both in vitro and in vivo. 
 
1.6 Research objectives 
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Although many research teams have been studying the removal of accumulated 
cholesterol as a therapy for NPC patients, these studies are not focused on the mechanisms 
underlying neurodegeneration. It is our expectation that detailed analysis of the pathways leading 
to neuronal dysfunction and death will identify currently unknown therapeutic targets. The work 
presented in this dissertation pursues mechanisms that protect against neurodegeneration and 
may serve as potential targets for future therapy development. The first objective is to explore 
the genetic interaction of NPC1 deficiency with deletion of cystatin B, an endogenous inhibitor 
of lysosomal cathepsins. In chapter 2, I will provide data implicating a cascade of LMP and 
cathepsin leakage as contributing to neurodegeneration due to NPC1 deficiency. I show that 
genetic or small molecule approaches to modulate cathepsin activity in mice and in cellular 
models of NPC disease alter cell viability and neurodegeneration. The second objective of this 
dissertation is to identify genes that protect neurons from the toxicity of NPC1 deficiency. In 
chapter 3, I explore genes that potentially modify neuronal survival and death in the NPC brain. 
To identify these genes, we analyze gene expression patterns in the cerebellum using 
bioinformatics tools to identify several candidate modifier genes. I confirm that one potential 
neuroprotective gene, HSPB1, promotes survival in cellular models of NPC disease through a 
mechanism involving the inhibition of apoptosis. Moreover, I confirm HSPB1 neuroprotective 
activity in an NPC mouse model using both overexpression and knock-down approaches. In 
conclusion, it is my underlying hope that uncovering pathways that lead to neurodegeneration in 
NPC1 deficiency will contribute to the identification of novel therapeutic targets. 
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Chapter 2 
 
Cystatin B, an endogenous inhibitor of lysosomal cathepsins, protects  
against Niemann-Pick C cerebellar degeneration 
 
2.1 Abstract 
Niemann-Pick C1 (NPC) disease, an autosomal recessive lipid trafficking disorder caused 
by loss-of-function mutations in the NPC1 gene, is characterized by progressive 
neurodegeneration resulting in cognitive impairment, ataxia and early death. Little is known 
about the cellular pathways leading to neuron loss, yet impairments of lysosomal protein quality 
control and decreased cathepsin activity have been documented in mutant cells. Here, we studied 
the effects of diminishing expression of cystatin B, an endogenous inhibitor of cathepsins B, H 
and L, on the development of neuropathology. We show that decreased expression of cystatin B 
in patient fibroblasts enhances cathepsin activity. Deletion of the encoding Cstb gene in Npc1 
deficient mice resulted in unexpected and deleterious effects, particularly within the cerebellum 
where diffuse loss of Purkinje cells was observed in young mice. This severe pathology occurred 
through cell autonomous mechanisms that triggered Purkinje cell death. Moreover, our analyses 
demonstrated the mislocalization of lysosomal cathepsins within the cytosol of Npc1 deficient 
Purkinje cells. We provide evidence that this may be a consequence of damage to lysosomal 
membranes by reactive oxygen species, leading to the leakage of lysosomal contents that 
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culminates in apoptotic cell death. The observation that Npc1 and Cstb deletion genetically 
interact to potently enhance the degenerative phenotype of the NPC cerebellum provides strong 
support for the notion that the lysosomal cell death pathway contributes to cerebellar 
degeneration in Niemann-Pick C disease.  
 
2.2 Introduction 
Lysosomes are critical components of the cellular degradation machinery and important 
nodes in the homeostatic response to metabolic demands (Settembre et al., 2013). These vesicles 
degrade macromolecules delivered to them through endocytosis or autophagy by the action of a 
family of acidic hydrolases including proteases, lipases, nucleases, glycosidases, phospholipases, 
phosphatases, and sulfatases (de Duve, 2005). More than 50 diseases related to lysosomal 
dysfunction, many caused by enzyme deficiencies, have been identified since Christian De Duve 
discovered this organelle in the mid-twentieth century (Schultz et al., 2011). 
Lysosomal proteases, or cathepsins, are required for the housekeeping function of these 
organelles in protein turnover. These cathepsins have been implicated in a variety of human 
diseases, including neurodegenerative disorders (Elrick et al., 2012; Nakanishi, 2003; 
Yamashima, 2000). Cathepsins are classified by their catalytic mechanism into aspartic, serine, 
threonine, metallo, or cysteine proteases (Pislar and Kos, 2014). Cysteine cathepsins, the largest 
family of lysosomal proteases, are synthesized as inactive precursors and are activated by 
cleavage in the acidic environment of the lysosome (Katunuma, 2010). While it was initially 
thought that lysosomal cysteine proteases are unstable and rapidly inactivated outside the 
lysosome, a number of studies have established that cysteine cathepsins are stable and partially 
active at neutral pH, such as within the cytoplasm (Turk et al., 1995; Turk et al., 1993; Turk et 
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al., 1994). Indeed, accumulating evidence suggests that the release of cathepsins into the cytosol 
triggers apoptotic cell death (Groth-Pedersen and Jaattela, 2013). A first line of self-defense in 
preventing apoptosis initiated through this mechanism is provided by intracellular inhibitors of 
cysteine proteases, the cystatins. Cystatin B, which inhibits cathepsins B, H and L, is a reversible 
and competitive inhibitor of these proteases (Turk and Bode, 1991). As such, cystatin B is poised 
to play an important role in limiting the activation of apoptosis in situations where cells are 
exposed to a variety of toxic challenges that impact lysosomal membrane integrity.  
Here we tested the extent to which cystatin B regulates neurodegeneration in Niemann-
Pick type C (NPC) disease, an autosomal recessive disorder characterized by progressive 
cognitive decline, seizures, dystonia, abnormal eye movements and early death (Vanier, 2013). 
The cause of NPC disease is loss-of-function mutations in the NPC1 or NPC2 genes (Carstea et 
al., 1997; Naureckiene et al., 2000) whose protein products act cooperatively in the efflux of 
cholesterol from late endosomes and lysosomes (Infante et al., 2008; Kwon et al., 2009). In NPC 
disease, the accumulation of unesterified cholesterol and glycosphingolipids in late endosomes 
and lysosomes is associated with impairments of cellular proteostasis, including abnormalities in 
autophagy (Elrick and Lieberman, 2013; Lieberman et al., 2012; Pacheco et al., 2007; Sarkar et 
al., 2013), accumulation of ubiquitinated proteins (Higashi et al., 1993; Liao et al., 2007; 
Ordonez et al., 2012) and impairment of lysosomal cathepsin activity (Elrick et al., 2012). These 
abnormalities correlate with the occurrence of severe neurodegeneration that is characterized, in 
part, by the loss of cerebellar Purkinje neurons.  However, little is known about the cellular 
pathways leading to neurodegeneration in this disorder. 
In this study, we present evidence that cystatin B is a potent modifier of cerebellar 
degeneration in NPC mice. We show that knockdown of cystatin B markedly increases cathepsin 
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activity in NPC1 deficient fibroblasts, and that deletion of the encoding Cstb gene enhances 
cerebellar degeneration in Npc1-/- mice. This accentuation of NPC neuropathology is shown to 
be neuron autonomous and due to enhanced apoptotic death of Purkinje cells. Our findings 
uncover an important pathway that regulates neuron loss in the NPC brain, and suggest that 
damage to organelle membranes by reactive oxygen species may be a significant contributor to 
disease.  
 
2.3 Results 
2.3.1 Cystatin B deficiency increases cathepsin activity in NPC1 patient fibroblasts. 
Previous studies demonstrated that deficiency of NPC1 results in impaired lysosomal 
cathepsin B activity, a defect that is driven by lysosomal lipid storage (Elrick et al., 2012). Here, 
we sought to reverse this defect by relieving the activity of cystatin B, an endogenous inhibitor 
of cathepsins B, H and L that has been shown to regulate enzymatic activity in models of cancer 
and neurodegenerative disease (Butinar et al., 2014; Chang et al., 2009; Yang et al., 2011). To 
accomplish this, we diminished expression of cystatin B (CSTB) in NPC1 patient fibroblasts by 
transfecting CSTB targeted siRNA. Cathepsin B activity in live cells was monitored using Magic 
Red, a fluorophore covalently bound to a di-arginine peptide motif. Prior to cleavage, Magic Red 
is cell permeable and non-fluorescent. After it is cleaved by cathepsin B in lysosomes, the dye 
fluoresces red. The rate of fluorescence accumulation was quantified and used to estimate 
cathepsin B activity in situ. In accordance with prior studies (Elrick et al., 2012), we found that 
cathepsin B activity in primary fibroblasts from NPC1 patients was reduced to approximately 
half of controls (Figure 2.1A). Cystatin B knockdown in NPC1 deficient cells increased 
cathepsin B activity to the level of unaffected controls (Figure 2.1A). This enhancement of 
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enzymatic B activity was associated with diminished cystatin B expression (Figure 2.1B). In 
contrast, we observed no change in the expression or maturation of cathepsin B. In addition, we 
observed no change in NPC1 protein expression (Figure 2.1B) or in the accumulation of filipin-
positive unesterified cholesterol (Figure 2.1C). We conclude that diminishing cystatin B 
expression in NPC1 deficient cells rescued defects in lysosomal cathepsin activity without 
altering lipid storage.  
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Figure 2.1 Cystatin B knockdown increases cathepsin B activity in NPC1 patient 
fibroblasts. Control fibroblasts and NPC1 deficient fibroblasts treated with non-targeted siRNA 
(NT siRNA) or cystatin B siRNA (CSTB siRNA) for 48 hrs were analyzed. (A) Relative 
cathepsin B activity. Data are mean ± SD, n = 3 independent experiments, *P < 0.05, **P<0.01. 
(B) Left panel, western blot analysis of the expression of NPC1, cathepsin B, cystatin B and 
GAPDH. Right panel, NPC1 and cathepsin B intensity relative to GAPDH (mean ± SD, n = 3, 
*P < 0.05).  (C) Unesterified cholesterol was stained by filipin and quantified across three 
independent experiments. Data are mean ± SD, n = 40-50 fields of cells per group in total, 
****P<0.0001. 
 
 
2.3.2 Cystatin B protects against Niemann-Pick C cerebellar degeneration.  
Niemann-Pick C disease is characterized by impaired proteostasis, as reflected by defects 
in macroautophagy (Elrick et al., 2012; Sarkar et al., 2013) and by the accumulation of 
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ubiquitinated proteins in the CNS (Elrick et al., 2012; Higashi et al., 1993; Liao et al., 2007; 
Love et al., 1995; Walkley and Suzuki, 2004).  We therefore sought to determine whether 
enhanced lysosomal cathepsin activity would modify the disease phenotype in mouse models. To 
accomplish this, we generated Npc1 null mice that were deficient in cystatin B. Mice with a 
cystatin B null allele were previously generated to model progressive myoclonic epilepsy of the 
Unverricht-Lundborg type. These mice begin to develop disease around 6 months of age that 
includes loss of cerebellar granule neurons, but not Purkinje cells. At earlier time points, between 
1 - 3 months, mutants are normal in body size, weight, behavior and histopathology compared to 
wild type littermates (Pennacchio et al., 1998). We therefore generated Npc1 and Cstb double 
null mice and focused our analysis on young animals. Unexpectedly, these double null mutants 
were generated at a very low frequency. Of the 101 Cstb -/- pups generated from multiple 
matings of Npc1 +/-, Cstb +/- adults, only 4% were homozygous for the Npc1 null allele. By chi-
squared analysis, only double null mutants (Npc1 -/-, Cstb -/-) were derived from these matings 
at a frequency that was significantly lower than expected (P < 0.001; see Table 2.1).  
 
Table 2.1 Expected and observed genotype ratios for pups 
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We observed a significant and unanticipated enhancement of the NPC phenotype in mice 
that were deficient in cystatin B. As early as 4 weeks of age, double null mutants showed marked 
deficits in body and liver weight compared to Npc1 nulls that were haploinsufficient or wild type 
for cystatin B (Figure 2.2A). We were unable to train these young double null mutants to cross a 
balance beam (data not shown), a motor task that is sensitive to Purkinje cell loss in Npc1 
deficient animals (Elrick et al., 2010). This severe, early onset behavioral impairment prompted 
us to perform histologic examination of the brains of these mice and littermate controls at 4 
weeks of age. Remarkably, the double null mutants contained virtually no cerebellar Purkinje 
cells, except for only rare neurons in lobule X (Figure 2.2B). At this age, there was no detectable 
Purkinje cell loss in either anterior or posterior cerebellar lobules of Npc1 or Cstb single null 
mutants. The loss of Purkinje cells in lobule X is particularly noteworthy since these neurons are 
typically resistant to toxic effects of Npc1 deficiency, even in animals aged to 6 months (Elrick 
et al., 2010). The paucity of calbindin-positive Purkinje cells in anterior and posterior cerebellar 
lobules of double null mutants was associated with marked astrocytic and microglial reaction 
(Figure 2.2C, D). In contrast, cystatin B deficiency did not exacerbate accumulation of the 
ganglioside GM2 or unesterified cholesterol in the brains of Npc1 deficient mice (Figure 2.2E, 
F), suggesting that mechanisms other than enhanced lipid storage led to the worsened phenotype. 
These analyses indicated that there was a genetic interaction between Npc1 and Cstb deficiency 
that markedly increased the severity of neuropathology.  
 While our initial studies focused on cerebellar Purkinje cells, they left unanswered 
whether other brain regions in Npc1 deficient mice showed enhanced pathology in the setting of 
Cstb deletion. To begin to address this question, we stained midline sagittal brain sections for 
GFAP since reactive astrocytes are sensitive indicators of damage in the CNS. We observed 
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marked gliosis that was largely restricted to the cerebellum and was only seen in double null 
mutants at 4 weeks of age (Figure 2.3A-D). This gliosis was associated with significant 
cerebellar atrophy (Figure 2.3E), which reflected the extensive loss of Purkinje neurons, the 
main output neurons of the cerebellum. Our findings indicate that cystatin B normally functions 
to protect the NPC cerebellum, and that deletion of the Cstb gene resulted in marked cerebellar 
atrophy and gliosis in young Npc1 deficient mice. 
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Figure 2.2 Phenotype of Npc1, Cstb null mice. (A) Body weight, at left, and liver weight, at 
right, of mice at 4 weeks of age (mean ± SD, n = 3-6 mice/genotype, *P<0.05, **P<0.01, 
***P<0.001). (B) Purkinje cell density in midline cerebellar sections at 4 weeks of age (mean ± 
SD, n = 3 mice/genotype, ****P<0.0001). (C, D) Immunofluorescent staining (red) for Purkinje 
cells (calbindin), astrocytes (GFAP), and microglia (Iba1) in cerebellar lobule III (C) and lobule 
X (D). Nuclei are stained with DAPI. Scale bar = 50 m. (E) Immunohistochemical staining of 
cerebral cortex for GM2 at 4 weeks of age. Scale bar = 200 m. (F) Filipin staining of cerebral 
cortex at 4 weeks of age. Scale bar = 100 m. 
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Figure 2.3 The cerebellum of Npc1, Cstb null mice is markedly gliotic and atrophic. Midline 
brain sections of mice at 4 weeks of age were stained by immunofluorescence for GFAP. (A) 
Npc1+/+, Cstb+/+, (B) Npc1-/-, Cstb+/+, (C) Npc1+/+, Cstb-/-, (D) Npc1-/-, Cstb-/-. Cb = 
cerebellum, Mb = midbrain, P = pons, C = cerebral cortex, Cc = corpus callosum, H = 
hippocampus, Th = thalamus, Ht = hypothalamus. Scale bar = 500 m. (E) Quantification of 
cerebellar area in midline sections (mean ± SD, n = 3/genotype, *P<0.05, **P<0.01). 
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2.3.3 Cystatin B deficiency triggers enhanced, cell autonomous Purkinje cell degeneration. 
We next sought to determine whether cystatin B deficiency exacerbated cerebellar 
degeneration in a cell autonomous manner. To accomplish this, we generated Cstb-/- mice that 
were deficient in Npc1 only in Purkinje cells by using a previously characterized conditional null 
allele (Elrick et al., 2010). Cre recombinase driven by the Pcp2 promoter resulted in transgene 
expression in Purkinje cells that initiated around postnatal day 6 and was present in all Purkinje 
cells by postnatal days 14 - 21 (Barski et al., 2000). Therefore, this strategy enabled post-
developmental and cell-type restricted deletion of Npc1. 
At 8 weeks of age, partial Purkinje cell loss restricted to anterior cerebellar lobules was 
detected in Npc1 Flox/-, Pcp2-Cre, Cstb +/+ mice, as previously reported (Elrick et al., 2010). In 
contrast, strikingly few Purkinje cells were observed in anterior and posterior cerebellar lobules 
of Npc1 Flox/-, Pcp2-Cre mice that were deficient in cystatin B (Figure 2.4A, B). Quantification 
confirmed that cystatin B deficiency significantly diminished soma size of Purkinje cells 
remaining in lobule X (Figure 2.4C) and enhanced neuron loss in anterior and posterior 
cerebellar lobules (Figure 2.4D). This exacerbation of Purkinje cell loss in Npc1 Flox/-, Pcp2-
Cre, Cstb-/- mice impacted the disease phenotype as it led to impaired motor function as 
measured by balance beam performance (Figure 2.4E).  
The paucity of Purkinje cells in adult double null mutant mice could reflect either a 
neurodevelopmental impairment or neurodegeneration. To distinguish between these 
possibilities, we examined Purkinje cell density in 3 week old Npc1 Flox/-, Pcp2-Cre, Cstb -/- 
mice (Figure 2.5A). These young mutants showed Purkinje neurons in all cerebellar lobules, 
although at a density that was lower than Npc1 Flox/-, Pcp2-Cre, Cstb +/+ controls. A 
comparison of Purkinje cell density jn Npc1 Flox/-, Pcp2-Cre, Cstb -/- mice at 3 and 8 weeks of 
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age revealed an age-dependent loss of neurons (Figure 2.5B). This was associated with the 
occurrence of Purkinje cells that stained for activated caspase-3 in the cerebellum of 3 week old 
Npc1 Flox/-, Pcp2-Cre, Cstb -/- mice (Figure 2.5C). We conclude that cystatin B deficiency 
triggered apoptotic death of Purkinje neurons in young Npc1 deficient mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Enhanced Purkinje cell loss following cystatin B deficiency is cell autonomous. 
(A) Immunofluorescent staining for Purkinje cells (calbindin antibody) at 8 weeks of age in the 
cerebellar midline. Left panel, Npc1 F/-, Pcp2-Cre, Cstb+/+; right panel, Npc1 F/-, Pcp2-Cre, 
Cstb-/-. Scale bar = 200 m. (B) Immunofluorescent staining for calbindin (red) in cerebellar 
lobules II, III, and X; nuclei were stained by DAPI. Scale bar = 50 m. (C) Quantification of 
Purkinje cell soma area (mean ± SD, n ≥ 45 cells/genotype, *P<0.05). (D) Purkinje cell density 
in lobules II, III and X was quantified in the cerebellar midline (mean ± SD, n = 4 
mice/genotype, *P<0.05, **P<0.01, ***P<0.001). (E) Balance beam performance at 8 weeks of 
age (mean ± SD, n ≥ 3 mice/genotype, **P<0.01). 
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Figure 2.5 Purkinje cell loss following cystatin B deficiency is due to neurodegeneration 
and not a neurodevelopmental deficiency. (A) Immunofluorescent staining of Purkinje cells 
(calbindin antibody) at 3 weeks of age in the cerebellar midline. Left panel, Npc1 F/-, Pcp2-Cre, 
Cstb+/+; right panel, Npc1 F/-, Pcp2-Cre, Cstb-/-. Scale bar = 200 m. (B) Purkinje cell density 
in lobules II, III and X was quantified in the cerebellar midline of 3-week-old Npc1 F/-, Pcp2-
Cre, Cstb-/- mice; data from 8-week-old Npc1 F/-, Pcp2-Cre, Cstb-/- mice (from Figure 2.4C) is 
shown for comparison (mean ± SD, n = 4, *P<0.05, **P<0.01). (C) Detection of apoptotic 
Purkinje cells by co-immunofluorescent staining for calbindin (red) and activated caspase-3 
(green) at 3 weeks of age in the cerebellar midline; nuclei were stained by DAPI. Top panel, 
Npc1 F/-, Pcp2-Cre, Cstb+/+; bottom panel, Npc1 F/-, Pcp2-Cre, Cstb-/-. Scale bar = 50 m. 
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2.3.4 Npc1 deficiency disrupts cathepsin localization in cerebellar Purkinje cells. 
To explore the mechanism by which cystatin B deficiency enhanced cerebellar 
degeneration in NPC mice, we considered the possibility that cathepsins were partially 
mislocalized outside lysosomes in the diseased brain, rendering Purkinje cells sensitive to 
cystatin B deletion and leading to apoptosis. This notion was based on prior work showing that 
cathepsin B is markedly increased in cytosolic fractions of cerebellar lysates from Npc1 deficient 
mice compared to controls (Amritraj et al., 2009). Furthermore, the release of cathepsins into the 
cytosol has been shown to trigger cell death (Groth-Pedersen and Jaattela, 2013). To determine 
cathepsin localization in Npc1 deficient Purkinje cells, we performed immunofluorescence 
staining for cathepsins B or L and LAMP-1, a marker of late endosomes and lysosomes (Figure 
2.6). Confocal microscopy demonstrated that the majority of the cathepsin signal in the cytosol 
of Purkinje cells co-localized with Lamp1 in Npc1 Flox/+, Pcp2-Cre mice, irrespective of the 
Cstb genotype. In contrast, co-localization of cathepsins with Lamp1 was significantly 
diminished in Npc1-/- Purkinje cells. These data indicated that disease was associated with an 
increased fraction of cathepsins outside Lamp1-positive vesicles, consistent with previous 
observations (Amritraj et al., 2009). Similar findings have been reported in a mouse model of 
Niemann-Pick type A (NPA) disease, a related neurodegenerative disorder caused by deficiency 
of acid sphingomyelinase (Gabande-Rodriguez et al., 2014). Notably, the mislocalization of 
cathepsins in Npc1-/- Purkinje cells was not influenced by Cstb genotype, suggesting that 
cystatin B deficiency exerted affects on disease phenotype by modulating cathepsin activity 
rather than localization.   
Enhanced cytoplasmic localization of cathepsins could reflect leakage of lysosomal 
contents due to organelle membrane damage. Indeed, prior studies have indicated that lysosomal 
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membrane permeabilization triggers cell death, and that this can occur after damage by reactive 
oxygen species (ROS) (Boya et al., 2003; Brunk et al., 1997; Cirman et al., 2004; Kagedal et al., 
2001). Analysis of the Npc1-/- mouse brain has demonstrated the occurrence of oxidative 
damage (Kennedy et al., 2013; Vazquez et al., 2012), and lipid oxidation products have emerged 
as a sensitive biomarker of NPC disease (Porter et al., 2010). Consistent with these observations, 
we found that cerebellar Purkinje cells deficient in Npc1 exhibited substantially more staining 
for superoxide dismutase 2 (SOD2) than controls, irrespective of Cstb genotype (Figure 2.7A).  
These observations prompted us to study the sensitivity of control and NPC1 patient fibroblasts 
to cytotoxicity induced by ROS. This approach is based on published studies demonstrating that 
ROS can trigger cell death by promoting lysosomal membrane permeabilization (Boya et al., 
2003; Brunk et al., 1997; Cirman et al., 2004; Kagedal et al., 2001). We used hydrogen peroxide 
as an oxidative stressor since it easily crosses membranes and induces formation of reactive 
hydroxyl radicals and iron-centered radicals (Terman et al., 2006). These free radicals destabilize 
the lysosomal membrane and induce lysosomal membrane permeabilization-dependent cell death 
(Krenn et al., 2015; Terman et al., 2006; Zhao et al., 2003). As shown in Figure 2.7B, NPC1 
deficient fibroblasts are significantly more sensitive to cytotoxicity induced by hydrogen 
peroxide than control fibroblasts, with mean lethal concentration 50 (LC50) values in NPC1 
deficient and control cells of 337.9 M (95% confidence intervals range 316.0 to 361.3) and 
486.8 M (95% confidence intervals range 465.4 to 509.1). To determine the extent to which 
cathepsins contributed to the cytotoxicity of NPC1 deficient cells exposed to hydrogen peroxide, 
we used genetic and pharmacological approaches to diminish cathepsin activity. Cystatin B 
overexpression rendered NPC1 deficient cells significantly more resistant to hydrogen peroxide-
induced cell death (Figure 2.7C). Similarly, treatment with CA-074 methyl ester (CA-074ME), 
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which is a selective, irreversible and membrane-permeable cathepsin B inhibitor (Buttle et al., 
1992; Towatari et al., 1991; Yamamoto et al., 1992), significantly increased cell viability 
following exposure to hydrogen peroxide (Figure 2.7D). Taken together, these data indicate that 
cathepsin activity contributes to the susceptibility of NPC1 deficient cells to ROS-induced 
cytotoxicity, and support a model in which lysosomal membrane permeabilization is a 
component of the cascade leading to neuron loss in the NPC brain.  
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Figure 2.6 Cathepsin mislocalization in Npc1 deficient Purkinje cells. Co-localization of 
cathepsin B or L with LAMP1 was examined in midline cerebellar sections of mice at 8 weeks of 
age. Immunofluorescent staining for LAMP1 (red) and cathepsin B (green, panel A) or cathepsin 
L (green, panel C) is shown; nuclei were stained by DAPI. Scale bar = 10 m. Co-localization 
of cathepsin B and LAMP1 (panel B) or cytosolic cathepsin L and LAMP1 (panel D) was 
quantified (mean ± SD, n=10 cells, pooled from three independent experiments, **P<0.01, 
***P<0.001, ****P<0.0001). 
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Figure 2.7 NPC1 deficient cells are more sensitive to oxidative damage and rescued by 
cathepsin B inhibition. (A) Immunofluorescence staining for SOD2 (green) and calbindin (red) 
at 3 weeks of age in the cerebellar midline; nuclei were stained by DAPI. Scale bar = 10 m. (B - 
D) Viability of primary fibroblasts was determined by XTT assay. Data are mean ± SD, n = 3 
independent experiments, normalized to untreated control cells. **P<0.01, ***P<0.001 (B) 
Control and NPC1 deficient fibroblasts were treated with increasing concentrations (0 - 2000 
M) of H2O2 for 24 hrs. (C) NPC1 deficient fibroblasts were transfected to express CSTB or 
vector control. After 48hr, cells were treated with increasing concentrations of H2O2 for 24 hrs. 
(D) NPC1 deficient fibroblasts were treated concurrently with 0 or 500 M H2O2, and with 
vehicle (DMSO) or 1M CA-074ME for 24 hrs.  
42 
  
 
 
43 
  
2.4 Discussion 
Recent biochemical and structural studies have provided important insights into the 
mechanisms by which the NPC1 and NPC2 proteins regulate intracellular lipid transport (Infante 
et al., 2008; Kwon et al., 2009). Nonetheless, pathways leading to the severe neurodegeneration 
that underlies the clinical phenotype of NPC disease have remained elusive. Here, we 
demonstrate that cystatin B, an endogenous inhibitor of lysosomal cathepsins B, H and L, plays a 
critical role in regulating Purkinje cell degeneration in NPC mice. We show that decreased 
expression of cystatin B in patient fibroblasts enhances cathepsin activity. Deletion of the 
encoding Cstb gene in Npc1 deficient mice results in unexpected and deleterious effects, 
particularly within the cerebellum where diffuse loss of Purkinje cells is observed. This severe 
pathology is shown to occur through cell autonomous mechanisms that trigger apoptotic Purkinje 
cell death. Moreover, our analyses corroborate data in the literature showing that lysosomal 
cathepsins are mislocalized within the cytosol of Npc1 deficient Purkinje cells (Amritraj et al., 
2009; Gabande-Rodriguez et al., 2014). We provide evidence that this may be a consequence of 
damage to lysosomal membranes by reactive oxygen species, leading to the leakage of lysosomal 
contents that culminates in neurodegeneration (Figure 2.8). The observation that Npc1 and Cstb 
deletion genetically interact to potently enhance the degenerative phenotype of the NPC 
cerebellum provides strong support for this proposed pathogenic mechanism. 
This model of disease takes into account the observation that Npc1 deficiency does not 
alter cathepsin maturation, a process that is dependent upon normal trafficking to lysosomes. 
Moreover, our data are consistent with reports from NPC and NPA mouse models in which 
enhanced cytosolic localization of cathepsins (Amritraj et al., 2009; Gabande-Rodriguez et al., 
2014) and the occurrence of oxidative damage within the CNS (Kennedy et al., 2013; Vazquez et 
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al., 2012) have been documented. Notably, a number of studies have demonstrated that 
cathepsins retain some activity at neutral pH (Turk et al., 1995; Turk et al., 1993; Turk et al., 
1994). Furthermore, in vitro experiments performed at neutral pH demonstrate that cathepsins B, 
H, L, S and K cleave Bid and induce release of cytochrome c from isolated mitochondria, 
leading to the activation of caspases (Cirman et al., 2004; Taylor et al., 2008). Prior studies have 
also shown that cystatin B deficiency sensitizes neurons or tumor cells to oxidative stress 
(Butinar et al., 2014; Lehtinen et al., 2009), observations that are consistent with our model. We 
note that cystatin B may exert additional protective effects on the survival of Purkinje cells 
through alternative mechanisms. For example, cystatin B has been shown to protect 
mitochondrial integrity following exposure to reactive oxygen species, independent of its action 
on lysosomal cathepsins (Maher et al., 2014). Accordingly, we can infer that cystatin B may 
exert beneficial effects on Purkinje cells by acting upon several distinct targets. 
The exquisite sensitivity of Npc1 deficient Purkinje neurons to the effects of cystatin B 
deletion is noteworthy. To glean insights into this observation, we queried the Allen Brain Atlas, 
an on-line database that contains quantitative three-dimensional expression data derived from in 
situ hybridizations performed on the adult mouse brain. In this database cystatin B expression is 
observed in the cerebellum, medulla and pons, while cathepsin B expression occurs widely 
throughout the central nervous system. Thus, cystatin B may function as a vital inhibitor of 
cathepsins in cerebellar Purkinje cells, while other mechanisms predominate in many other brain 
regions. Additional factors may also contribute to Purkinje cell degeneration in double null 
mutant mice, such as increased sensitivity to reactive oxygen species that leads to enhanced 
lysosomal membrane damage. Our studies offer insights into mechanisms underlying neuron loss 
in NPC disease and suggest potential strategies to ameliorate this process. Indeed, a cathepsin 
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inhibitor has been shown to abrogate death of cortical neurons in vitro following treatment with 
U18666A, a small molecule that mimics the NPC phenotype (Amritraj et al., 2009). These 
findings suggest that targeting the lysosomal cell death pathway may be beneficial in preventing 
neurodegeneration in NPC disease. Our data provide critical support that this pathogenic cascade 
underlies neuronal loss in NPC disease, an insight that provides a foundation for the future 
development of therapeutic strategies. 
 
Figure 2.8 Model of cerebellar neurodegeneration in NPC1 disease. NPC1 deficiency results 
in increased production of reactive oxygen species, which damage lysosomal membranes, 
promote leakage of cathepsins into the cytosol, and lead to apoptotic death of Purkinje cells. 
Cystatin B functions to block this cascade by inhibiting cytosolic cathepsins. 
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2.5 Materials and Methods 
2.5.1 Reagents 
Magic Red cathepsin B assay kit (cat. 938) was from Immunochemistry Technologies. 
Fluorescent dextran (D3305) and BODIPY 493/503 (D3922) was from Life Technologies. 
Filipin (F9765) and all other chemicals were from Sigma-Aldrich. Antibodies used in this study 
were anti-NPC1 (Abcam, ab36983), anti-GAPDH (Santa Cruz, sc-25578), anti-glial fibrillary 
acidic protein (GFAP) (Dako, Z0334), anti-Iba1 (Wako, 019-19741), anti-calbindin (Sigma-
Aldrich, c2724), anti-cathepsin B (Abcam, ab33538), anti-cathepsin L (Athens Research and 
Technology, 01-12-030112), anti-cystatin B (Sigma-Aldrich, C5243), anti-SOD-2 (Novus 
Biologicals, NB100-1992) and anti-caspase-3 (cell signaling, 9664). Anti-GM2 antibody was a 
gift from Dr. Kostantin Dobrenis (Albert Einstein College of Medicine). 
 
2.5.2 Mice 
Mice containing the flox and null Npc1 alleles  and the Pcp2-Cre transgene were 
generated and genotyped as described previously (Elrick et al., 2010). Mice with a cystatin B 
null allele were initially from Dr. Richard Myers (Pennacchio et al., 1998). All lines were 
backcrossed to C57BL6/J for ≥10 generations. All animal procedures were approved by the 
University of Michigan Committee on the Use and Care of Animals. 
 
2.5.3 Behavioral testing 
Motor function was measured by balance beam test. Mice at 7 weeks of age were trained 
on three consecutive days to cross a 6 mm wide beam suspended at 50 cm. Mice were then tested 
in triplicate at 8 weeks of age. Data are reported as average time to traverse the beam, allowing a 
maximum of 25 sec and scoring falls as 25 sec. 
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2.5.4 Filipin staining 
Human fibroblasts (Coriell Cell Repositories, control, GM08399; NPC1 P237S/ 
I1061T, GM03123) were grown in chamber slides (Lab-Tek, 154526), rinsed with PBS, and 
fixed with 4% paraformaldehyde for 30 min. After washing with PBS, cells were incubated with 
1.5 mg/ml glycine for 10 min, washed with PBS and stained with 0.05 mg/ml filipin, 0.02 mg/ml 
BODIPY and 10% FBS in PBS for 2 hrs at room temperature. Stained cells were imaged by 
focusing on the BODIPY channel. Filipin images were captured with the UV filter set on a Zeiss 
AxioImager Z1 microscope. Quantitative analysis of filipin images from more than 5 
fields/experiment was performed by NIH ImageJ software as described previously (Yu et al., 
2012). Data reported are from three independent experiments. For mouse brain staining, tissue 
embedded in Optimal Cutting Temperature (OCT) compound (Tissue-Tek) was sectioned at 10 
m and stained as described above. Representative images are from one of three mice per 
genotype. 
 
2.5.5 Immunofluorescence staining 
5 m sections from brains embedded in paraffin were deparaffinized with xylenes and 
ethanol. Sections were boiled in 10 mM sodium citrate, pH 6, for 10 min for antigen retrieval. 
After washing with water, sections were blocked with 5% goat serum and 1% BSA in PBS for 1 
hr and then incubated in primary antibody (calbindin 1:500, LAMP1 1:10, cathepsin B 1:50, 
cathepsin L 1:100, GFAP 1:1000, Iba1 1:1000, caspase-3 1:200, SOD-2 1:200) diluted in 1.5% 
blocking solution overnight at 4o C. Sections were subsequently incubated in secondary 
antibodies conjugated to Alexa Fluor 594 or 488 for 2 hrs and mounted with mounting medium 
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including DAPI (Vector Lab, H-1200). Images were captured on an Olympus FluoView 500 
Confocal microscope. Co-localization was quantified using Zeiss MetaMorph imaging software. 
  
2.5.6 Gene knockdown  
ON-TARGET plus SMART pool cystatin B siRNA (Dharmacon, L-017240-00-0005) 
and ON-TARGET plus non-targeting pool (Dharmacon, D-001810-10-05) were used to 
modulate gene expression. Cells were transfected with 10 l of 10 M siRNA using the 
Nucleofector II (Lonza, program U-23) following the manufacturer’s instructions. 
 
2.5.7 Cathepsin B assay 
Control or NPC1 deficient fibroblasts were transfected with siRNA as indicated in the 
figure legend, cultured in a chamber slide (Lab-Tek, 1554096), and analyzed for cathepsin B 
activity after 48 hrs, as described previously (Elrick et al., 2012). Briefly, the cells were 
incubated with a 1:3000 dilution of cathepsin B-specific Magic Red reagent and imaged using a 
Deltavision-RT Live Cell Imaging System. Images were captured at 1 min intervals for 20 min. 
Fluorescence at 554/25 nm excitation and 609/25 nm emission was quantified using NIH ImageJ. 
Total fluorescence intensity above threshold was plotted as a function of time, and the slope of 
the line was used to determine cathepsin B activity. 
 
2.5.8 Immunohistochemical staining 
10 m sections from brains embedded in OCT were boiled in 10 mM sodium citrate, pH 
6, for 10 min. After washing with PBS, tissue sections were treated with 3% hydrogen peroxide 
for 10 min to quench endogenous peroxidase activity. Sections were blocked with 5% goat 
serum, 1% BSA, 0.02% saponin in PBS for 1 hr and then stained overnight at 4o C with a GM2 
49 
  
antibody (1:15) diluted in 1.5% blocking solution. Sections were subsequently incubated with a 
biotinylated anti-mouse antibody (1:400) for 2 hrs at room temperature. Vectastain Avidin-Biotin 
Complex (ABC) reagent (Vector lab, PK4001) and a peroxidase substrate (DAB) reagent 
(Vector lab, SK4100) were used to detect the biotinylated secondary antibody. Representative 
images in the figure are from one of three mice per genotype. 
 
2.5.9 Morphological analysis 
Purkinje cell density and cerebellar area were quantified in midline sagittal sections 
stained with hematoxylin and eosin. For cell density, Purkinje cells were recognized as large 
cells with amphophilic cytoplasm, large nuclei with open chromatin and prominent nucleoli that 
were located between the molecular and granular layers. The number of cells was normalized to 
the length of the Purkinje layer, as measured by NIH ImageJ software. For cerebellar area, the 
cerebellum was selected and measured by NIH ImageJ, and pixel size was converted to mm2 
using the scale bar as a calibration standard. For analysis of Purkinje cell soma size, calbindin 
staining was used to define the cell soma. The area was measured as described above for analysis 
of cerebellar area. 
 
2.5.10 Western blotting 
Cells were lysed in RIPA buffer (Thermo Scientific) containing Complete protease 
inhibitor (Roche) and Halt phosphatase inhibitor (Thermo Scientific). Protein concentrations 
were measured by the Bio-Rad DC protein assay kit (Bio-Rad) and normalized. Proteins were 
separated by 4 - 20% gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to nitrocellulose membranes using a semidry electrophoretic transfer 
apparatus (BioRad). Immunoreactivity was detected by TMA-6 (Lumigen) or ECL (Thermo 
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Scientific). Antibodies used were anti-cathepsin B (1:500), anti-cystatin B (1:10000), anti-
GAPDH (1:5000) and anti-NPC1 (1:1000). Each protein band was selected and quantified by 
ImageJ software after subtracting the background signal. Specific band intensity was normalized 
to GAPDH.  
 
2.5.11 Cell viability assay 
Control or NPC1 deficient fibroblasts were treated with the indicated doses of H2O2 for 
24 hrs. Cells viability was determined by XTT assay (ATCC, 30-1011K) following the 
manufacturer’s instructions. In brief, 50l XTT was added in 100l cell culture medium and 
cells were incubated for 4 hrs in a CO2 incubator at 37
o C. The plates were assessed 
spectrophotometrically at 490 nm for specific absorbance and at 650 nm for non-specific 
absorbance using a microplate reader. For cystatin B overexpression, Nucleofector II (Lonza, 
program U-23) was used to transfect cells with the indicated plasmids. After 48 hrs, cells were 
treated with H2O2 for 24 hrs and tested for viability. To inhibit cathepsin B activity, 1M CA-
074ME was used. 
 
2.5.12 Statistics 
Statistical significance was assessed by unpaired Student’s t test (for comparison of two 
means) or ANOVA (for comparison of more than two means). Statistics were performed using 
the Prism 6.02 software (GraphPad). P values less than 0.05 were considered significant. 
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Chapter 3 
 
Heat shock protein beta-1 modifies anterior to posterior Purkinje cell 
vulnerability in a mouse model of Niemann-Pick type C disease 
 
3.1 Abstract 
Selective neuronal vulnerability is characteristic of most degenerative disorders of the 
CNS, yet mechanisms underlying this phenomenon remain poorly characterized. Many forms of 
cerebellar degeneration exhibit an anterior-to-posterior gradient of Purkinje cell loss including 
Niemann-Pick type C1 (NPC) disease, a lysosomal storage disorder characterized by progressive 
neurological deficits that often begin in childhood. Here, we describe an approach to identify 
candidate genes underlying vulnerability of Purkinje cells in anterior cerebellar lobules using 
data freely available in the Allen Brain Atlas. This approach led to the identification of 16 
candidate neuroprotective or susceptibility genes. We demonstrate that one candidate gene, heat 
shock protein beta-1 (HSPB1), promoted neuronal survival in cellular models of NPC disease 
through a mechanism that involved inhibition of apoptosis. Additionally, we show that HSPB1 
over-expression in NPC mice slowed the progression of motor impairment and diminished 
cerebellar Purkinje cell loss. We confirmed the modulatory effect of Hspb1 on Purkinje cell 
degeneration in vivo, as knockdown by Hspb1 shRNA significantly enhanced neuron loss. These 
results suggest that strategies to promote HSPB1 activity may slow the rate of cerebellar 
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degeneration in NPC disease, and highlight the use of bioinformatics tools to uncover pathways 
leading to neuronal protection in neurodegenerative disorders. 
 
3.2 Introduction 
Selective vulnerability of specific neuronal populations is a well characterized, though 
often perplexing feature of many neurodegenerative diseases (Double et al., 2010). Most 
commonly, these disorders are initiated by a uniform stress to the entire CNS, such as a genetic 
mutation, toxic insult, or aging. However, only a subset of neurons respond to these stressors by 
degenerating, while others remain resistant and apparently maintain their normal function 
(Schultz et al., 2011). Although this phenomenon is widely observed, the underlying mechanisms 
remain poorly understood. Notably, the factors regulating neuronal vulnerability represent 
attractive therapeutic targets, with the potential to convert susceptible neuronal populations into 
ones that are disease resistant. 
One particularly striking example of selective vulnerability is the degeneration of 
cerebellar Purkinje cells (Sarna and Hawkes, 2003). Purkinje cells represent the sole output of 
the cerebellar cortex. Loss of Purkinje cells, therefore, leads to significant deficits of motor 
coordination, including ataxia and tremors. Despite the apparent similarity of Purkinje cells in 
their morphology, connectivity, and electrophysiological properties, many cerebellar disorders 
affect Purkinje cells in a non-uniform way, leading to a distinct spatiotemporal pattern of loss 
that is reproducible not only between cases of a single disease, but across many otherwise 
unrelated diseases and injuries. One common pattern reveals a strong resistance of Purkinje cells 
in lobule X to degeneration, contrasted with the exquisite sensitivity of the anterior zone (lobules 
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II-V), and moderate susceptibility of the intermediate (lobules VI-VII) and posterior zones 
(lobule VIII and rostral aspect of lobule IX). Superimposed onto this anterior-to-posterior 
gradient is often a pattern of parasagittal stripes in which differential vulnerability is also 
observed (Sarna and Hawkes, 2003). Diseases displaying the classic anterior-to-posterior 
gradient may arise from genetic mutations, including spinocerebellar ataxias type 1 (Clark et al., 
1997) and 6 (Takahashi et al., 1998), late infantile neuronal ceroid lipofuscinosis (Sleat et al., 
2004), saposin C deficiency, a rare cause of Gaucher Disease (Yoneshige et al., 2010), ataxia 
telangiectasia (Tavani et al., 2003), and Niemann-Pick disease types A/B (Sarna et al., 2001) and 
C (Sarna et al., 2003); sporadic disorders, including multiple system atrophy (Kume et al., 1991) 
and chronic epilepsy (Crooks et al., 2000); toxins, including alcohol (Torvik and Torp, 1986), 
cytosine arabinoside (Winkelman and Hines, 1983), methotrexate (Ciesielski et al., 1994); 
hypoxia/ischemia (Biran et al., 2011; Welsh et al., 2002); paraneoplastic syndromes (Mizutani et 
al., 1988); and even normal aging (Andersen et al., 2003). This pattern is also seen in many 
spontaneous mouse mutants, including pcd (Wang and Morgan, 2007), leaner (Heckroth and 
Abbott, 1994), toppler (Duchala et al., 2004), robotic (Isaacs et al., 2003), shaker (Tolbert et al., 
1995), and lurcher (Armstrong et al., 2010); or targeted mutants, such as saposin D knockout 
(Matsuda et al., 2004), prion protein knockout (Rossi et al., 2001), and overexpression of the 
prion protein related gene doppel (Anderson et al., 2004). The fact that such a diverse array of 
insults leads to the same pattern of Purkinje cell death suggests that selective vulnerability of 
Purkinje cell subpopulations arises not from the initiating event of the disease process, but 
instead from differential regulation of cellular survival or death pathways in response to these 
injuries. We hypothesize that the identification of pathways responsible for this phenomenon will 
yield therapeutic targets broadly applicable to this large class of cerebellar disorders. 
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As a model for patterned Purkinje cell loss, we have studied murine Niemann-Pick type 
C1 disease (NPC). NPC is caused by mutations in the genes encoding NPC1 or NPC2 proteins, 
which are thought to act cooperatively in the efflux of cholesterol from late endosomes (LE) and 
lysosomes (LY) (Carstea et al., 1997; Kwon et al., 2009; Naureckiene et al., 2000). The 
consequence of these mutations is the accumulation of cholesterol and glycosphingolipids in the 
LE/LY compartment, leading to neurodegeneration by mechanisms that are not yet understood 
(Vanier and Millat, 2003). We recently demonstrated that conditional deletion of Npc1 in 
Purkinje cells leads to a purely cell autonomous degeneration that recapitulates the 
spatiotemporal pattern of cell loss observed in mice with germline Npc1 deletion (Elrick et al., 
2010). Further, because Purkinje cell death does not cause early mortality in these mice, we were 
able to follow Purkinje cell survival beyond the typical lifespan of NPC mice. During this period, 
the population of surviving Purkinje cells in lobule X remained stable, while neurodegeneration 
continued to progress in lobules II-IX, thus highlighting the strong resistance of these cells to 
degeneration. Given the cell autonomous nature of Purkinje cell loss in NPC, we hypothesized 
that this selective vulnerability arises from intrinsic biological differences that are driven by 
differential gene expression. To test this notion, here we used a bioinformatics approach to 
identify genes that are differentially expressed between disease-resistant and vulnerable Purkinje 
cell populations. To test the biological function of these differentially expressed genes, we used 
in vitro and in vivo model of NPC and characterized the ability of one of these candidate genes to 
protect neurons from degeneration. 
 
3.3 Results 
3.3.1 Identification of candidate genes underlying selective vulnerability of Purkinje cells 
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Using mice containing a conditional null allele of the Npc1 gene, we found that gene 
deletion in Purkinje cells recapitulates the spatiotemporal pattern of neuron loss observed in mice 
with global germline deletion of Npc1 (Figure 3.1A) (Elrick et al., 2010; Sarna et al., 2003). The 
population of surviving Purkinje cells is located within posterior lobules of the cerebellar 
midline, while age-dependent progressive Purkinje cell loss is observed anterior lobules (Figure 
3.1B) (Elrick et al., 2010). We hypothesized that differential gene expression underlies this 
selective neuronal vulnerability. To search for genes differentially expressed between Purkinje 
cell subpopulations, we utilized the Allen Brain Atlas (Figure 3.1C). This resource contains 
quantitative three-dimensional expression data derived from in situ hybridizations for greater 
than 20,000 genes in the adult C57BL6/J mouse brain (Lein et al., 2007). The complete gene 
expression dataset was downloaded and used to construct a single expression matrix with spatial 
coordinates and gene identifiers arrayed on separate axes. This strategy allowed us to treat the 
data for each location in the brain analogously to a single microarray experiment. The 
coordinates corresponding to cerebellar lobule X, the location of the most resistant Purkinje 
cells, and lobules II and III, the most highly vulnerable, were defined as regions of interest 
(Figure 3.1B). For analysis, all coordinates falling within one region of interest were treated as 
replicate microarray experiments. This approach allowed us to use bioinformatics tools 
developed for microarray analysis to query the Allen Brain Atlas dataset. Differential gene 
expression between lobules was determined by t-test and Significance Analysis of Microarrays 
(SAM) (Tusher et al., 2001), followed by manual curation of in situ hybridization images. 
Manual curation was required to remove false positives created by expression in non-Purkinje 
cell types and technical artifacts in the archived images. 
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Initial analysis revealed 234 differentially expressed genes, of which 185 were more 
highly expressed in lobules II and III and 49 were more highly expressed in lobule X. We next 
sought to prioritize this list to identify testable candidates with putative roles in promoting or 
preventing neurodegeneration. The Allen Brain Atlas data, being derived from in situ 
hybridizations, presented a challenge in this regard, as expression levels were regarded as semi-
quantitative. Further, because expression data within each z plane came from the same 
hybridization experiment, they were not considered statistically independent samples. For these 
reasons, we were unable to rank the gene list by either the magnitude of differential expression 
or the degree of significance. Instead, we prioritized genes whose expression differences were 
absolute and tightly correlated with Purkinje cell survival in midline cerebellar sections. To 
accomplish this, we only included genes whose expression was undetectable in one region of 
interest, and whose expression matched or was the inverse of the survival pattern in 20 week old 
Npc1 flox/-;Pcp2-Cre mice: strong in lobule X, patchy throughout the intermediate and posterior 
zones, with additional sparing in the caudal aspect of lobule IX and a region spanning the caudal 
aspect of lobule VI and rostral lobule VII (Figure 3.1A). This yielded sixteen candidate 
neuroprotective or susceptibility genes (Figure 3.3A, Table 3.1); in situ hybridization images 
from the Allen Brain Atlas for the candidate genes highly expressed in regions of cell survival 
are shown in Figure 3.2. 
 
Figure 3.1 Schematic of gene expression analysis. (A) Calbindin staining of cerebellum from 
20-week old Npc1 flox/-, Pcp2-Cre mouse, demonstrating survival pattern of Purkinje cells in 
midline. Scale bar = 500 m. (B) Schematic of differential vulnerability of Purkinje cell 
subpopulations. Regions of interest (ROI) were selected to include the population that 
experiences the most rapid neurodegeneration (lobules II and III, ROI #1) or the population that 
does not degenerate (lobule X, ROI #2). (C) Approach to gene expression analysis. Allen Brain 
Atlas data was downloaded and consolidated into a single gene expression matrix. Each row 
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represents gene expression data from a single series of in situ hybridization data, while each 
column represents a single voxel within the mouse brain. The data set was then narrowed to 
include only voxels lying within the defined regions of interest. To identify genes differentially 
expressed between regions of interest, expression data was treated analogously to replicate 
microarrays and subjected to standard statistical tests (t-test and Significance Analysis for 
Microarrays). The top 1000 most significant genes were accepted for manual curation to verify 
expression in Purkinje cells. The gene list was further narrowed to include only genes with 
absolute expression differences between regions of interest, and expression matching the pattern 
of Purkinje cell survival or death throughout the entire cerebellum. 
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Table 3.1 Genes differentially expressed in Purkinje cells in anterior or posterior lobules 
Gene  
symbol 
Gene name Gene ID 
Region of 
expression 
B3galt5 
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, 
polypeptide 5 
93961 posterior 
Hspb1 heat shock protein beta-1 15507 posterior 
Pde1b phosphodiesterase 1B, Ca2+-calmodulin dependent 18574 posterior 
Plcxd2 
phosphatidylinositol-specific phospholipase C, X domain 
containing 2 
433022 posterior 
Prkcd protein kinase C, delta 18753 posterior 
Th tyrosine hydroxylase 21823 posterior 
Alpk2 alpha-kinase 2 225638 anterior 
Bace1 beta-site APP cleaving enzyme 1 23821 anterior 
Chml choroideremia-like 12663 anterior 
Chst8 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 68947 anterior 
Dbc1 deleted in bladder cancer 1 56710 anterior 
Kcnh7 
potassium voltage-gated channel, subfamily H (eag-related), 
member 7 
170738 anterior 
Lgr5 leucine rich repeat containing G protein coupled receptor 5 14160 anterior 
Opn3 opsin (encephalopsin) 13603 anterior 
Prkca protein kinase C, alpha 18750 anterior 
Sgpp2 sphingosine-1-phosphate phosphotase 2 433323 anterior 
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Figure 3.2 Genes selectively expressed in posterior lobules of the cerebellar midline.  In situ 
hybridization images from the Allen Brain Atlas.  
 
We analyzed the functions of these candidate genes and their human orthologs by 
querying their gene ontology (GO) annotations using AmiGO (Carbon et al., 2009). The GO 
Term Enrichment tool revealed significant over-representation (p<0.01) for GO terms containing 
Prkca, Prkcd, and Plcxd2, members of the phospholipase C – protein kinase C signal 
transduction cascade, suggesting that this pathway is differentially regulated between regions of 
interest. AmiGO was also used to query the complete list of GO Biological Process terms 
associated with candidate genes. In support of our hypothesis that the differentially expressed 
genes would include regulators of cellular survival and death decisions, 5 genes were associated 
with cell death related annotations, including “cell death” (GO:0008219, Dbc1 and Hspb1), 
“apoptosis” (GO:0006915, Pde1b and Prkcd), “negative regulation of apoptosis” (GO:0043066, 
Hspb1), and “induction of apoptosis by intracellular signals” (GO:0008629, Prkca). 
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Furthermore, the gene product of Sgpp2, sphingosine 1-phosphate phosphatase 2, is likely 
involved in the regulation of apoptosis as well due to its hydrolysis of sphingosine 1-phosphate 
(Ogawa et al., 2003), a lipid second messenger that is a negative regulator of apoptosis (Spiegel 
and Milstien, 2003). Finally, we performed an analysis of Cellular Component annotations to 
determine the subcellular localization of the protein products of candidate genes (Figure 3.3B). 
The vast majority of gene products are localized outside of the endosome-lysosome system, 
further suggesting that selective vulnerability of Purkinje cell populations arises not from the 
primary site of pathogenesis in NPC disease, but from responses to cellular stress that take place 
elsewhere.  
Figure 3.3 Candidate neuroprotective or pro-degenerative genes. (A) Hierarchical 
clustering of candidate genes, demonstrating strong differential expression between regions of 
interest. Rows, genes; columns, individual voxels within the regions of interest. Red designates 
higher and green designates lower expression. (B) Subcellular localization of candidate genes, 
based on GO terms and review of supporting literature.  
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3.3.2 HSPB1 promotes survival of in vitro models of NPC disease 
We next sought to directly test the extent to which candidate genes influence cell survival 
in models of NPC disease. For this initial analysis, we chose to study one gene that was over-
expressed by lobule X Purkinje cells, heat shock protein beta 1 (Hspb1). This gene has been 
linked previously to neurodegeneration, as mutations in human HSPB1 cause some cases of 
Charcot-Marie-Tooth disease and distal hereditary motor neuropathy (Evgrafov et al., 2004). 
Additionally, HSPB1 regulates multiple events that influence neuronal viability, including 
stability of the actin cytoskeleton, protein folding, reactive oxygen species (ROS), and apoptosis 
(Arrigo, 2007), and its robust expression has been documented in surviving Purkinje cells from 
Npc1-/- mice (Sarna et al., 2003).  
We initially sought to confirm that Hspb1 expression in mutant mice with active disease 
matched the pattern predicted by the Allen Brain Atlas. Strong expression of Hspb1 was detected 
in lobule X Purkinje cells of Npc1 flox/-;Pcp2-Cre mice at 7 weeks of age, prior to the 
significant Purkinje cell degeneration (Figure 3.4A). In contrast, Hspb1 was undetectable in the 
more susceptible Purkinje cells of lobules II and III. To determine whether HSPB1 functions as 
an inhibitor of cell death pathways in NPC cell models, we knocked down its expression using 
siRNA. We initially treated HeLa cells with U18666A, a small molecule which induces lipid 
trafficking defects identical to those seen in NPC disease (Liscum et al., 1989). Knockdown of 
HSPB1 in U18666A-treated cells, but not in vehicle controls, led to a significant increase of 
caspase activity (Figure 3.4B). Likewise, HSPB1 knockdown in NPC patient fibroblasts 
significantly increased the percentage of cells with chromatin condensation, while HSPB1 
knockdown had no effect on control fibroblasts (Figure 3.4C). These results are consistent with 
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a model in which HSPB1 prevents the induction of cell death in response to the intracellular lipid 
trafficking defects caused by NPC1 deficiency.  
To initially test the role of HSPB1 in the survival of neurons, the cell type critical for 
NPC disease neuropathology (Elrick et al., 2010; Ko et al., 2005; Yu et al., 2011), we utilized a 
neuronal culture model. Primary cortical neurons treated with U18666A develop filipin-positive 
lipid inclusions and progressive degeneration, and have been used previously to model NPC 
disease (Amritraj et al., 2009; Cheung et al., 2004). Neurons treated with U18666A demonstrated 
progressive degeneration, and exogenous over-expression of HSPB1 almost completely 
prevented this death (Figure 3.4D). To probe the mechanism of this effect, we took advantage of 
the fact that serine phosphorylation is critical for HSPB1-mediated protection against neuronal 
damage in vitro and in vivo (Stetler et al., 2012) . Mutation of these residues to alanine (non-
phosphorylatable) or aspartate/glutamate (phosphomimetic) has been widely used to study 
phosphorylation state-dependent properties of HSPB1 (Arrigo, 2007). Transduction of 
U18666A-treated neurons with the phosphomimetic HSPB1-3E recapitulated the neuroprotective 
effects of wild-type HSPB1, while non-phosphorylatable HSPB1-3A was inactive (Figure 3.4D). 
We conclude that the neuroprotective effects of HSPB1 in NPC cell models are mediated by the 
phosphorylated species. 
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Figure 3.4 HSPB1 promotes survival in cellular models of NPC1 disease. (A) Expression of 
Hspb1 (left panel) and calbindin (right panel, Purkinje cells) in cerebellar midline of Npc1 flox/-, 
Pcp2-Cre mice 7 weeks. Scale bar = 200 m. (B) (Upper panel) HeLa cells were transfected 
with non-targeted (lanes 1 and 3) or HSPB1 siRNA (lanes 2 and 4), then treated with vehicle 
(lanes 1-2) or 1 g/ml U18666A (lanes 3-4) for 24 hr. HSPB1 expression was determined by 
western blot. GAPDH controls for loading. (Lower panel) Caspase-3 in HeLa cell lysates. Data 
are mean ± SEM. *p<0.05. (C) NPC1 patient fibroblasts were transfected with non-targeted or 
HSPB1 siRNA. Cells were stained with Hoechst, and the percentage of cells with condensed 
chromatin was scored. Data are mean ± SEM. **p<0.01. (D) Primary mouse cortical neurons 
were transduced with wild type HSPB1, HSPB13A, HSPB13E, or empty vector, and then treated 
with 2.5 µg/ml U18666. XTT assay was performed 72 hrs post U18666A. Neuron survival is 
reported relative to vehicle treated cells. Data are mean ± SEM. ***p<0.001.  
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3.3.3 HSPB1 over-expression diminishes motor impairment and Purkinje cell loss 
We next sought to determine whether HSPB1 over-expression impacts Purkinje cell 
survival and motor impairment in NPC mice. To accomplish this, we generated mice deficient in 
Npc1 only in Purkinje cells by using a previously characterized conditional null allele (Elrick et 
al., 2010). Cre recombinase expression driven by the Pcp2 promoter initiated around postnatal 
day 6 and was present in all Purkinje cells by postnatal days 14 - 21 (Barski et al., 2000). 
Therefore, this strategy enabled post-developmental as well as cell-type restricted deletion of 
Npc1. Expression of the hemagglutinin (HA)-tagged human HSPB1 cDNA transgene was driven 
by the chicken -actin promoter and cytomegalovirus enhancer. These transgenic mice express 
exogenous HSPB1 in brain, spinal cord, heart, muscle, liver, kidney, lung, and pancreas, and 
exhibit normal reproductive patterns, longevity and behavior (Akbar et al., 2003) . We 
determined the behavioral effect of HSPB1 over-expression on Npc1 deficiency by measuring 
the time to traverse a balance beam. Purkinje cell specific null mutants (Npc1 flox/-;Pcp2-Cre), 
but not littermate controls (Npc1 flox/+;Pcp2-Cre), displayed a progressive, age-dependent 
behavioral impairment beginning at 10 weeks (Figure 3.5A), consistent with our previous study 
(Elrick et al., 2010). HSPB1 over-expression significantly rescued motor performance in mice at 
10 and 15 weeks of age (Figure 3.5A). Previous work has demonstrated that this motor task is a 
sensitive measure of Purkinje cell loss in Npc1 deficient mice (Elrick et al., 2010). To determine 
the extent to which HSPB1 over-expression improved neuron survival, we examined the density 
of Purkinje cells in the cerebellar midline of mice at 11 weeks. This analysis revealed that 
HSPB1 over-expression significantly rescued Purkinje cell density in posterior (lobules VIII-X) 
but not anterior cerebellar lobules (Figure 3.5B, C-J). Purkinje cell rescue in posterior lobules 
was confirmed by immunofluorescence staining for calbindin, a marker of Purkinje cells (Figure 
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3.5G versus I). This rescue was associated with the expression of HA-tagged HSPB1 transgene 
(Figure 3.5H versus J). Transgene expression was also noted in anterior lobules, suggesting that 
HSPB1 over-expression alone was insufficient to account for effects on neuron survival. The 
HSPB1 transgene did not alter the accumulation of ubiquitinated proteins or filipin-positive 
unesterified cholesterol in Purkinje cells of posterior lobules (Figure 3.6). We conclude that 
exogenous HSPB1 protects Purkinje cells in posterior lobules and delays the onset of behavioral 
impairment, without altering the aberrant accumulation of proteins or cholesterol. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 HSPB1 over-expression rescues motor impairment and Purkinje cell loss. (A) 
Age-dependent performance on balance beam indicates that transgenic HSPB1 over-expression 
delays motor impairment in Npc1 flox/-, Pcp2-Cre mice. Data are mean ± SD, n ≥ 7 
mice/genotype. ***p<0.001. (B) Purkinje cell density in indicated lobules of the cerebellar 
midline of 11-week-old mice. Data are mean ± SD, n = 3 mice/genotype. *p<0.05. (C - J) 
Purkinje cells (calbindin, in red) and transgenic HSPB1 (HA, in green) in anterior and posterior 
lobules of the cerebellar midline of 11-week-old mice. Top row, lobule II; bottom row, lobule IX. 
Scale bar = 50 m. 
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Figure 3.6 HSPB1 over-expression does not rescue accumulation of ubiquitinated proteins 
or unesterified cholesterol. 
Sections of the cerebellar midline were examined from mice at 11 weeks of age. (A) 
Immunofluorescent staining for calbindin (green) and ubiquitin (red); nuclei were stained by 
DAPI. (B) Immunofluorescent staining for calbindin (red) and filipin (blue). Scale bar = 20 m. 
 
 
 
To further explore the basis of the beneficial effects of HSPB1 on select Purkinje cell 
subpopulations, we first evaluated whether the transgene was uniformly expressed. HA staining 
of the cerebellar midline confirmed diffuse reactivity of Purkinje cells in 7 week old Npc1 
flox/-;Pcp2-Cre, HSPB1 mice (Figure 3.7A). We next considered the possibility that HSPB1 
was differentially activated in cerebellar lobules. Because phosphorylation of HSPB1 influences 
its ability to promote neuronal survival in vitro (Figure 3.4D), we examined HSPB1 
phosphorylation state in Purkinje cells using phospho-HSPB1 [pS15] immunofluorescence. 
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Strikingly, only Purkinje cells in posterior lobules were positive for phospho-HSPB1 (Figure 
3.7B) despite the fact that the transgene was diffusely expressed (Figure 3.7A). Intriguingly, our 
expression analysis identified restricted expression of the HSPB1 kinase PKC (Gaestel et al., 
1991; Lee et al., 2005; Maizels et al., 1998) to Purkinje cells in the posterior lobules (Figure 3.2, 
Table 3.1), a finding that was confirmed by immunofluorescence staining (Figure 3.7C). Taken 
together, these data indicated that phosphorylation of HSPB1 was tightly associated with 
Purkinje cell rescue in animals expressing the transgene. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 PKC and phosphorylated HSPB1 are co-expressed in Purkinje cells in 
posterior lobules. (A) Transgenic HSPB1 (HA) in the cerebellar midline of 7-week-old Npc1 
flox/–, Pcp2-Cre, HSPB1 mice. Scale bar = 200 m. (B, C) Expression of phospho-HSPB1 
(serine 15, in green, panel B) and PKC (in green, panel C) were examined in Purkinje cells 
(calbindin, in red) in the cerebellar midline of Npc1 flox/–, Pcp2-Cre, HSPB1 mice at 7 weeks of 
age. Nuclei were stained by DAPI. Top row, lobule II; bottom row, lobule IX. Scale bar = 20 m. 
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3.3.4 Hspb1 knockdown exacerbates Purkinje cell loss 
Our over-expression studies demonstrated that HSPB1 delays motor impairment and 
Purkinje cell loss in posterior cerebellar lobules. We next sought to determine the effects of 
Hspb1 knockdown in the NPC mouse cerebellum. The feasibility of this approach was supported 
by prior work demonstrating that Hspb1 null mice are viable and fertile, without obvious 
morphological abnormalities (Huang et al., 2007). To accomplish gene knockdown, we used an 
adeno-associated virus serotype 2 (AAV2) vector to produce a short hairpin RNA (shRNA) 
driven by the U6 promoter. Hspb1 shRNA was cloned into an AAV2 shuttle plasmid 
(pFBAAV/mU6mcsCMVeGFP). To initially confirm knockdown efficiency, NIH3T3 cells were 
transfected to express non-targeted (NT) or Hspb1 shRNA, heat shocked, and analyzed by 
western blot (Figure 3.8A). These targeted and control shRNA clones were then used for virus 
generation, and injected into the deep cerebellar nuclei of Npc1 flox/-;Pcp2-Cre mice at 7 weeks. 
Animals were examined six weeks post-infection. At this time point, calbindin staining for 
Purkinje cells was markedly diminished in the posterior cerebellar lobules of mice receiving 
Hspb1 shRNA (Figure 3.8B). We confirmed viral transduction of remaining Purkinje neurons by 
GFP staining and assessed knockdown efficiency by Hspb1 staining. We observed diffuse GFP 
reactivity of Purkinje cells in mice expressing NT and Hspb1 shRNA, whereas Hspb1 staining 
was specifically diminished by Hspb1 shRNA (Figure 3.8C). Quantification of Purkinje cell 
density confirmed a significant exacerbation of neuron loss in posterior cerebellar lobules 
(lobules VII-IX) of mice expressing Hspb1 shRNA (Figure 3.8D). Furthermore, although 
Purkinje cell density was not altered in lobule X, Hspb1 knockdown significantly diminished 
soma size (Figure 3.8E). These data indicate that Hspb1 knockdown exacerbates Purkinje cell 
degeneration due to NPC1 deficiency. 
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Figure 3.8 Hspb1 knockdown exacerbates Purkinje cell loss. (A) NIH3T3 cells were 
transfected with NT shRNA or Hspb1 shRNA. After 24 hrs, cells were heat shocked (43o C for 
90 min) and protein lysates were collected after 24 hrs. Hspb1 expression was determined by 
western blot. Hsp90 controls for loading. (B - D) 7-week-old Npc1 flox/-, Pcp2-Cre mice were 
injected with AAV2 expressing non-targeted shRNA (NT shRNA) or Hspb1 shRNA, and then 
examined at 13 weeks of age. (B) Immunofluorescent staining of Purkinje cells (calbindin) in the 
cerebellar midline. Left panel, NT shRNA; right panel, Hspb1 shRNA. Roman numerals identify 
lobules. Scale bar = 500 m. (C) Expression of AAV2-encoded GFP (green) and endogenous 
Hspb1 (red). Top row, NT shRNA; middle and bottom rows, Hspb1 shRNA. Nuclei were stained 
by DAPI. Scale bar = 20 m. (D) Quantification of Purkinje cell density by lobule. Data are 
mean ± SD, n = 3 mice/genotype. *p<0.05, ***p<0.001. (E) Quantification of Purkinje cell soma 
area in lobule X. Data are mean ± SD, n ≥ 91 cells/genotype. **p<0.01. 
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3.4 Discussion 
Many progressive neurological diseases are characterized by the selective vulnerability of 
neuronal populations, yet mechanisms underlying this phenomenon remain poorly characterized. 
Here, we report a bioinformatics approach to the identification of potential modifier genes that 
influence the susceptibility of neurons to disease. Using NPC disease as a model for the study of 
selective neuronal vulnerability, we demonstrate that one of the candidate genes we identified, 
HSPB1, promotes neuronal survival in cellular model systems through a mechanism that likely 
involves phosphorylation-dependent inhibition of apoptosis. Additionally, we show that HSPB1 
over-expression in vivo slows the progression of motor impairment and diminishes cerebellar 
Purkinje cell loss. The neuroprotection from Npc1 deficiency afforded by HSPB1 over-
expression in mice was associated with HSPB1 phosphorylation and expression of the kinase 
PKC. We confirmed the modulatory effect of Hspb1 on Purkinje cell degeneration in vivo, as 
knockdown by Hspb1 shRNA significantly enhanced neuron loss. This effect of Hspb1 gene 
knockdown was particularly robust, resulting in Purkinje cell degeneration in posterior lobules 
(VII-IX) that approached the severity observed in anterior cerebellar lobules. Although 
diminished Hspb1 expression did not trigger Purkinje neuron loss in lobule X, we observed a 
significant decrease in soma size, a compensatory change reported in other degenerative ataxias 
to regulate membrane excitability (Dell'Orco et al., 2015). These results highlight the novel use 
of bioinformatics tools to uncover pathways leading to neuronal protection in neurodegenerative 
disorders. 
HSPB1 is a multifunctional protein with documented roles in actin stability, protein 
folding, oxidative damage, and apoptosis (Arrigo, 2007). Interestingly, HSPB1 is a direct 
inhibitor of apoptosis at multiple levels, through binding and sequestration of cytochrome c 
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(Bruey et al., 2000) and caspase-3 (Pandey et al., 2000), and inhibition of Bax activation (Havasi 
et al., 2008) and DAXX signaling (Charette and Landry, 2000). The phosphorylation state 
required for most of these activities is unknown, with the exception of DAXX inhibition, which 
requires phosphorylated HSPB1 (Charette and Landry, 2000). Recently, phosphomimetic 
mutants of HSPB1 were shown to protect against a broad array of apoptosis-inducing stimuli, 
while non-phosphorylatable mutants showed no protection against some stimuli and only mild 
protection against others, suggesting that anti-apoptotic activities of HSPB1 are primarily 
attributable to the phosphorylated species (Paul et al., 2010). Although both phosphorylated and 
dephosphorylated HSPB1 have chaperone activity (Ehrnsperger et al., 2000; Jakob et al., 1993) 
and prevent oxidative damage (Preville et al., 1999), it is unlikely that these functions play a 
primary role in exerting beneficial effects in NPC models. This conclusion is based on the tight 
association that we observed between HSPB1 phosphorylation and neuroprotection, and the 
finding that neuronal rescue is not associated with diminished accumulation of ubiquitinated 
proteins. Instead, we favor a model in which HSPB1 acts through a direct anti-apoptotic 
mechanism. Interestingly, our bioinformatics screen also identified the expression of PKC in 
disease-resistant Purkinje cells. This kinase has been shown to phosphorylate Hspb1 at Ser-15 
and Ser-86 to reduce apoptosis (Gaestel et al., 1991; Lee et al., 2005; Maizels et al., 1998), 
suggesting that these two proteins may act together to promote Purkinje cell survival. We note 
the possibility that other kinases also contribute to the regulation of Hspb1 activity in the 
cerebellum. Nonetheless, our findings suggest that strategies that promote HSPB1 expression or 
phosphorylation may diminish the rate of cerebellar degeneration in NPC disease. 
Our identification of candidate disease modifying genes relied on quantitative in situ 
hybridization data available in the Allen Brain Atlas. Methods had not been developed 
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previously to use this resource for unbiased studies of differential gene expression. For guidance 
in designing our approach, we looked to tools developed for the analysis of microarray data, 
where studies of differential gene expression are commonplace. Several caveats exist when 
applying our strategy to Allen Brain Atlas data. First, this method is heavily dependent upon 
manual curation as standard statistical tests yielded high false positive rates. These were variably 
due to signals generated by other cell types that fell within or adjacent to the region of interest, or 
artifacts and noise on the in situ hybridization images. Second, while the majority of 
differentially expressed genes were identified by both t-test and SAM, others were found only by 
one method. Therefore, it was necessary to combine the use of both approaches, and it remains 
possible that some differentially expressed genes were not discovered by either. To streamline 
future studies, a more robust method for working with Allen Brain Atlas data may need to be 
developed. Despite these technical limitations, our study provides proof of concept for the use of 
Allen Brain Atlas data to identify therapeutic targets in neurodegenerative disease. This method 
is readily applicable to any brain region, and could be used to discover novel therapeutic targets 
in other neurodegenerative diseases.  
 
3.5 Materials and Methods 
3.5.1 Antibodies 
Antibodies used in this study were anti-GAPDH (Santa Cruz, sc-25578), anti-calbindin 
(Sigma-Aldrich, c2724), anti-HSPB1 (abcam, ab5579), anti-Hspb1 (Enzo Life Sciences, SPA-
801), anti-HSPB1 phospho-Ser 15 (Novus, NBP1-60864), anti-PKC (Fisher, BDB610397), 
anti-hemagglutinin (HA) (Covance, 16B12), anti-GFP (Novus, NB 100-1770), anti-Hsp90 (Santa 
Cruz, sc-7947) and anti-ubiquitin (Dako, Z0458). 
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3.5.2 Mice 
Mice containing the Npc1 floxed (exon 9) (Elrick et al., 2010) and null alleles (Loftus et 
al., 1997), and transgenic mice expressing the Cre transgene driven by the Pcp2 promoter 
(Zhang et al., 2004) were generated and genotyped as described previously. Transgenic mice 
over-expressing hemagglutinin tagged human HSPB1 were from Dr. Jacqueline de Belleroche 
(Imperial College, London, UK) (Akbar et al., 2003). All lines were backcrossed to C57BL6/J 
for ≥10 generations. All animal procedures were approved by the University of Michigan 
Committee on the Use and Care of Animals. 
 
3.5.3 Cell culture 
All cell lines were cultured at 37°C with 5% CO2. HeLa cells were maintained in DMEM 
(Gibco, 11965-092) supplemented with 10% FBS, 1X penicillin, streptomycin, and glutamine 
(Gibco, 10378-016). Human skin fibroblasts GM03123 from an NPC patient and GM08399 from 
an age and sex matched control (Coriell Cell Repositories) were maintained in MEM (Gibco, 
10370-021) supplemented with 15% FBS, 1X penicillin, streptomycin, and glutamine (Gibco). 
To manipulate HSPB1 expression, cells were transfected with ON-TARGETplus SMART pool 
human HSPB1 or non-targeting control (Dharmacon). HeLa cells were transfected using the 
DharmaFECT reagent (Dharmacon), according to the manufacturer’s instructions. Fibroblasts 
were transfected by electroporation with the Lonza Nucleofector normal human dermal 
fibroblast kit. 
 
3.5.4 Genome-wide expression profiling 
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The Expression Energy Volume for each gene in the Allen Mouse Brain Atlas was 
downloaded via the Allen Brain Atlas API (Lein et al., 2007). These data were then reorganized 
into a single expression matrix and filtered to include locations corresponding to the regions of 
interest, cerebellar lobules X and II/III, and extending laterally 1400 microns from the midline. 
This data matrix was then loaded into TM4 MultiExperiment Viewer software (Saeed et al., 
2003), in which differential expression between regions of interest was determined by Student’s 
t-test and Significance Analysis of Microarrays (SAM) (Tusher et al., 2001). The top 1000 genes 
returned by each method were manually verified by direct inspection of in situ hybridization data 
on the Allen Brain Atlas website in midline and several adjacent sagittal sections. Criteria for 
validation were (1) expression present in the Purkinje cell layer in at least one region of interest, 
and (2) differential expression between regions of interest.  
 
3.5.5 Western blotting 
Cells were lysed in RIPA buffer (Thermo Scientific) containing Complete protease 
inhibitor (Roche) and Halt phosphatase inhibitor (Thermo Scientific). Samples were 
electrophoresed through a 10% SDS-PAGE gel, and then transferred to nitrocellulose 
membranes (BioRad) using a semidry transfer apparatus. Primary antibodies were anti-HSPB1 
(1:1000), anti-Hsp90 (add dilution) and anti-GAPDH (1:5000). HRP-conjugated secondary 
antibodies were from BioRad. Blots were developed using ECL (Thermo Scientific) or TMA-6 
(Lumigen) chemilluminescent reagents, following manufacturers’ protocols. 
 
3.5.6 Apoptosis assays 
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Caspase-3 activity in HeLa cells was determined by assaying DEVDase activity in cell 
lysates using the ApoTarget caspase 3 / CPP32 fluorimetric protease assay kit (Biosource) 
according to the manufacturer’s instructions. Fluorescence was measured using a SpectraMax 
Gemini EM plate reader (Molecular Devices). NPC fibroblasts were stained with Hoechst 
(Immunocytochemistry Technologies). Cells were counted in five randomly selected fields per 
transfection at 200x magnification and scored for chromatin condensation. 
 
3.5.7 Primary cortical neuron culture and viability assay 
Cortices from P0 C57BL6/J mouse pups were dissected free of meninges, minced, and 
then dissociated and cultured as described previously (Jakawich et al., 2010). Neurons were 
plated in poly-D-lysine (Millipore) treated 96-well plates at a density of 6x104 cells per well. 
Cytosine arabinoside (Sigma) was added to the culture media the following day at a final 
concentration of 5 µM to prevent glial growth. U18666A was added at 2.5 µg/ml at 7 div to 
induce lipid storage. Neuronal viability was determined by XTT assay (Cell Proliferation Kit II, 
Roche) following the manufacturer’s instructions. 
 
3.5.8 Viral vectors 
A lentiviral expression clone of human HSPB1 with a C-terminal FLAG tag was obtained 
from Genecopoeia. Serine-to-alanine and serine-to-glutamate mutations were introduced at 
serines 15, 78, and 82 using the QuikChange Lightning Multi Site-Directed Mutagenesis kit 
(Stratagene). Wild type HSPB1, HSPB1-3A, HSPB1-3E, and empty vector plasmids were 
packaged into feline immunodeficiency virus (FIV) vectors by the Iowa Vector Core. Viral 
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infection of cultured primary neurons was performed at 10 MOI, followed by a 75% media 
change four hours after infection. 
 
For in vivo gene targeting, Hspb1 shRNA was designed and cloned by the Iowa Vector 
Core. The target region in the Hspb1 sequence was analyzed using siSPOTR and potential 
miRNA target sequences of 21 nucleotides were identified based on low GC content and other 
factors, as described (Boudreau et al., 2013). Five potential target sequences were cloned in 
pFBAAV/mU6mcsCMVeGFP. Knockdown efficiency was tested in NIH3T3 cells. The most 
efficient plasmid was used in producing AAV2/1mU6miHspb1-CMVeGFP triple transfection 
virus. Non-targeted virus, AAV2/1mU6-miSafe-CMV eGFP, was used as a control. Before 
injection, virus was dialyzed at 4o C for 3hrs against 7,000 MWCO Slide -A-Lyzer mini-dialysis 
units (Thermo Scientific) in a custom buffer formulation distributed through the Gene Transfer 
Vector Core in University of Iowa.  
 
3.5.9 Stereotaxic cerebellar viral delivery.  
Stereotaxic administration of AAV2 was performed on 7 week-old Npc1 flox/-, Pcp2-Cre 
mice placed under anesthesia using a mixture of O2 and isoflurane (dosage 4% for induction, 
1.5% maintenance). Mice received bilateral intracerebellar injections (two sites/hemisphere) of 
virus. For each injection, ~1.4 × 1012 vg/ml of virus (4 µl) was delivered to the medial or lateral 
cerebellar nucleus at an infusion rate of 0.5 µl/min using a 10-µl Hamilton syringe (BD). One 
min after the infusion was completed, the micropipette was retracted 0.3 mm and allowed to 
remain in place for 4 min prior to complete removal from the mouse brain. Anterior–posterior 
coordinates were calculated separately for medial and lateral injection into each cerebellar 
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hemisphere. The coordinates for the medial injection were -6.4 mm anterior-posterior, ±1.3 mm 
medial-lateral and 1.9 mm dorsal-ventral as measured from bregma. The coordinates for the 
lateral injection were -6.0 mm anterior-posterior, ± 2.0 mm medial-lateral and 2.2 mm dorsal-
ventral as measured from bregma.  
 
3.5.10 Immunofluorescence staining 
5 m sections from brains embedded in paraffin were deparaffinized with xylenes and 
ethanol. Sections were boiled in 10 mM sodium citrate, pH 6, for 10 min for antigen retrieval. 
After washing with water, sections were blocked with 5% goat serum and 1% BSA in PBS for 1 
hr and then incubated in primary antibody (calbindin 1:500, PKC 1:50, Hspb1 1:100, HA 1:200, 
phospho-Hspb1 1:50, GFP 1:100, ubiquitin 1:200) diluted in 1.5% blocking solution overnight at 
4o C. Sections were subsequently incubated in secondary antibodies conjugated to Alexa Fluor 
594 or 488 for 2 hrs and mounted with mounting medium including DAPI (Vector Lab, H-1200). 
Images were captured on an Olympus FluoView 500 Confocal microscope.  
 
3.5.11 Behavioral testing 
Motor function was measured by balance beam test. Mice at 4 weeks of age were trained 
on three consecutive days to cross a 6 mm wide beam suspended at 50 cm. Mice were then tested 
in triplicate at 5, 10, 15 and 20 weeks of age. Data are reported as average time to traverse the 
beam, allowing a maximum of 25 sec and scoring falls as 25 sec. 
 
3.5.12 Morphological analysis 
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Purkinje cell density was quantified in midline sagittal sections stained with hematoxylin 
and eosin or calbindin staining. Purkinje cells were recognized as large cells with amphophilic 
cytoplasm, large nuclei with open chromatin and prominent nucleoli that were located between 
the molecular and granular layers or as calbindin positive cells. The number of cells was 
normalized to the length of the Purkinje layer, as measured by NIH ImageJ software. For 
analysis of Purkinje cell soma size, calbindin staining was used to define the cell soma. The cell 
soma was selected and measured by NIH ImageJ, and pixel size was converted to m2 using the 
scale bar as a calibration standard. 
 
3.5.13 Filipin staining 
Mouse brain tissue embedded in Optimal Cutting Temperature (OCT) compound (Tissue-
Tek) was sectioned at 10 m in midline. The sections were rinsed with PBS, and fixed with 4% 
paraformaldehyde for 30 min. After washing with PBS, the sections were incubated with 1.5 
mg/ml glycine for 10 min, washed with PBS and stained with 0.05 mg/ml filipin and 10% FBS 
in PBS for 2 hrs at room temperature. Filipin images were captured with the UV filter set on an 
Olympus FluoView 500 confocal microscope. Representative images are from one of three mice 
per genotype. 
 
3.5.14 Statistics 
Statistical significance was assessed by unpaired Student’s t test (for comparison of two 
means) or ANOVA (for comparison of more than two means). The Newman-Keuls post hoc test 
was performed to carry out pairwise comparisons of group means if ANOVA rejected the null 
hypothesis. Statistical analyses were performed using the software package Prism 4 (GraphPad 
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Software). P values less than 0.05 were considered significant. Statistical analysis of gene 
expression data was performed using TM4 MultiExperiment Viewer software (Saeed et al., 
2003). For these calculations, statistical significance was determined using Student’s t-test with 
Bonferroni correction for multiple comparisons and Significance Analysis of Microarrays (SAM) 
(Tusher et al., 2001). 
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Chapter 4 
 
 
Conclusion 
 
In this dissertation, I have explored several approaches to understanding the mechanisms 
leading to severe neurodegeneration in Niemann-Pick type C (NPC) disease. I demonstrated that 
cystatin B, an endogenous inhibitor of cathepsins B, H, and L, plays a critical role in regulating 
Purkinje cell degeneration in NPC mice. My data support a model in which NPC1 deficiency 
increases reactive oxygen species (ROS), leading to lysosomal membrane permeabilization 
(LMP). Cathepsin leakage through LMP triggered death of Purkinje cells, and inhibition of 
cytosolic cathepsins protected NPC1-deficient cells from degeneration. Using another approach 
to understanding neurodegeneration, I identified genes that protect neurons from the toxicity of 
NPC1 deficiency using a bioinformatics analysis. I determined that one potentially 
neuroprotective gene, HSPB1, promotes survival in cellular models of NPC disease by means of 
a mechanism involving the inhibition of apoptosis. I showed that HSPB1 protects Purkinje cells 
in an NPC mouse model using both overexpression and knockdown approaches. In this last 
chapter, I will discuss relevant questions that remain unanswered and suggest future directions 
for this work. 
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4.1 Genetic interaction of NPC1 deficiency with cystatin B deletion 
In chapter 2, I determined that cystatin B was involved in regulating Purkinje cell 
degeneration in NPC disease. At the beginning of the project, I expected that reduced cystatin B, 
an endogenous inhibitor of cathepsin B, L, and H, would modify NPC disease. This expectation 
was based on previous studies showing that NPC disease is characterized by impaired 
proteostasis, as reflected by defects in macroautophagy and reduced lysosomal cathepsin activity 
(Elrick et al., 2012; Sarkar et al., 2013). Ubiquitinated proteins have also been shown to 
accumulate in the CNS of NPC1 deficient mice (Elrick et al., 2012; Higashi et al., 1993; Liao et 
al., 2007; Love et al., 1995; Walkley and Suzuki, 2004). Thus, I hypothesized that decreased 
cystatin B would restore autolysosomal cargo degradation, leading to modification of the disease 
phenotype. To accomplish this, I diminished expression of cystatin B in NPC1 patient fibroblasts 
using CSTB siRNA. As expected, cystatin B knockdown rescued lysosomal protease function 
without decreasing lipid storage.  
I therefore sought to determine the effect of enhanced cathepsin activity on NPC mice. 
To accomplish this, I used Cstb null mice. In a prior study, the effects of reversing autophagy 
dysfunction in a transgenic mouse model of Alzheimer’s disease (TgCRND8 mice) was 
evaluated by generating mice that were deficient in cystatin B. This TgCRND8 mouse was 
characterized by enlarged autolysosomes, decreased cathepsin activity, and impaired lysosomal 
turnover of proteins, including the amyloid-β peptide (Yang et al., 2011). Rescue of autophagy 
dysfunction by Cstb deficiency in the Alzheimer’s disease mouse ameliorated amyloid 
pathologies (Yang et al., 2011). Based on this study and NPC cellular data, I anticipated that 
Npc1 null mice that were deficient in cystatin B would recover due to enhanced cathepsin 
activity.  
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Unexpectedly, Npc1 and Cstb double null mice were born at a very low frequency and 
showed enhancement of the NPC phenotype. Although the phenotype of these double null mice 
was unanticipated, they showed that cystatin B could be a pivotally protective gene in 
neurodegeneration occurring in NPC disease. Because cystatin B null mice were originally 
generated to model progressive myoclonic epilepsy of the Unverricht-Lundborg type, it might be 
that cystatin B deficiency would exaggerate neurodegeneration which is caused by NPC1 
deficiency due to synthetic lethality. In an attempt to avoid this, I restricted my analysis to mice 
at a young age. Cystatin B null mice begin to develop disease around 6 months of age. 
Symptoms include loss of cerebellar granule neurons but not Purkinje cells. At earlier time 
points, from 1 to 3 months, mutants are normal in body size, weight, behavior, and 
histopathology compared to wild type littermates (Pennacchio et al., 1998). In this study, I 
investigated the Npc1 and Cstb double null mice at 4 weeks of age, prior to the onset of 
neurodegeneration due to cystatin B deficiency.  
Since the double null mice displayed severe motor impairment, we looked for 
neuropathology in the cerebellum and documented marked accentuation of Purkinje neuron loss. 
To screen for neuropathology in other brain regions, we stained midline sagittal brain sections 
for GFAP since reactive astrocytes are sensitive indicators of damage in the CNS. Interestingly, 
marked gliosis and atrophy was restricted to the cerebellum in germ, line double null mice. This 
result raised a new question: Why does the Cstb deficiency affect primarily the cerebellum in 
global double null mice? We arrived at an answer by looking in the Allen Brain Atlas database. 
According to information in the database, cystatin B is expressed in the medulla and the 
cerebellum, especially in Purkinje cells (http://mouse.brain-map.org/experiment/show/1344). 
Also, reports indicate that most neurons in the adult rat cerebellum do not express detectable 
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amounts of cystatin B, with the exception of Purkinje cells and some cells of the molecular layer 
of the cerebellar folia (Riccio et al., 2005). In the human cerebellum, cystatin B is present in only 
Purkinje cells and Bergmann glial fibers (Riccio et al., 2005). Because cystatin B is mostly 
expressed in Purkinje cells, germ line deletion of cystatin B was expected to particularly affect 
Purkinje cells.  
The severe Purkinje cell loss in cystatin B and Npc1 deficiency occurred through cell 
autonomous mechanisms that triggered apoptotic Purkinje cell death. Moreover, our data showed 
that lysosomal cathepsins are mislocalized within the cytosol of Npc1 deficient Purkinje cells. I 
provided evidence showing that this may be a consequence of damage to lysosomal membranes 
by reactive oxygen species (ROS), leading to the leakage of lysosomal contents and culminating 
in neurodegeneration (Figure 2.8). This model is consistent with reports from NPC and 
Niemann-Pick type A (NPA) mouse models in which cytosolic (extra-lysosomal) localization of 
cathepsins was enhanced (Amritraj et al., 2009; Gabande-Rodriguez et al., 2014).  
An important, unanswered question is how cytosolic cathepsin mislocalization is 
increased by NPC1 deficiency. There are several stimuli that have been reported to trigger LMP: 
lysosomotropic detergents, viral proteins, bacterial toxins, ROS, proteases, lipids, and p53 (Aits 
and Jaattela, 2013). Interestingly, sphingosine has been found to induce LMP, leading to 
relocation of lysosomal cathepsins to the cytoplasm (Ullio et al., 2012). Because NPC deficient 
cells accumulate not only cholesterol but also sphingomyelin (Devlin et al., 2010), gangliosides 
(particularly GM2 and GM3) (te Vruchte et al., 2004; Zervas et al., 2001; Zhou et al., 2011), 
sphingosine (Lloyd-Evans et al., 2008), and bis(monoacylglycero) phosphate (Chevallier et al., 
2008; Kobayashi et al., 1999) in late endosomes and lysosomes (LE/Lys), accumulated 
sphingosine may act as an endogenous lysosomotropic detergent. However, the extent to which 
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sphingosine accumulates in NPC1 deficient cells is incompletely defined. The study reporting 
sphingosine accumulation in NPC1 deficiency did not use cells deficient in NPC1, but rather 
treated wild type cells with U18666A, a small molecule that induces an NPC-like defect in 
intracellular lipid trafficking (Lloyd-Evans et al., 2008). Nonetheless, the possibility that 
sphingosine contributes to LMP and cathepsin leakage in NPC1 deficiency is intriguing and 
deserves further close evaluation. 
Another factor that may contribute to the induction of LMP is p53. In myeloid leukemia 
cells, induced p53 is sufficient to cause LMP by lysosomal destabilization, leading to 
mitochondrial outer membrane permeabilization (Yuan et al., 2002). Phosphorylated p53 binds 
to LAPF (lysosome-associated and apoptosis-inducing protein containing PH and FYVE 
domains) and localizes to lysosomes. This complex triggers LMP in a transcription-independent 
manner, leading to apoptosis (Li et al., 2007). However, in Npc1 null mice, p53 is efficiently 
degraded by an Mdm2-dependent mechanism as the result of abnormal p38 MAPK activation 
(Qin et al., 2010). Due to low levels of p53 in NPC deficiency, I believe that p53 is a less likely 
candidate for the inducer of LMP in disease. 
In chapter 2, I suggested that ROS are an important factor that increases LMP in NPC1 
deficient cells. ROS are known to contribute to LMP via a number of oxidative stimuli such as 
drugs, heavy metals, and ionizing radiation and in conditions such as ischemia, inflammation, 
and neurodegenerative disorders (Kurz et al., 2008a). In cells treated with hydrogen peroxide, 
which easily crosses membranes and catalyzes Fenton reactions with lysosomal iron, free 
radicals destabilize the lysosomal membrane and induce LMP (Kurz et al., 2008b). Also, ROS 
might trigger LMP by activating Ca2+ channels such as transient potential receptor melastatin-2 
(TRPM2) (Sumoza-Toledo and Penner, 2011). Indeed, in prior studies, oxidative damage has 
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been observed in analysis of the NPC mouse brain (Kennedy et al., 2013; Smith et al., 2009; 
Vazquez et al., 2012) and in different cell models (Zampieri et al., 2009). Also, lipid oxidation 
products are considered to be specific and sensitive biomarkers for NPC disease (Porter et al., 
2010). However, the mechanism leading to ROS production in NPC deficiency is unclear. 
One mechanism that could underlie ROS production in NPC1 deficiency is mitochondrial 
dysfunction due to mitochondrial cholesterol accumulation. In fact, mitochondrial dysfunction 
appears to be a key element in many neurodegenerative diseases (Caspersen et al., 2005; 
Manfredi and Xu, 2005; Martin et al., 2006; Takuma et al., 2005). However, the role of 
mitochondrial dysfunction in NPC disease remains unknown. In previous studies, the level of 
mitochondrial cholesterol was reportedly elevated in NPC deficient cells (Charman et al., 2010; 
Kennedy et al., 2014; Lucken-Ardjomande et al., 2007) and in Npc1 null mice (Fernández et al., 
2009; Yu et al., 2005). These data should be interpreted carefully because it is difficult to obtain 
pure mitochondria, uncontaminated by lysosomes. However, treatment with the cyclodextrin, 
which removes cholesterol, restores ATP synthesis and mitochondrial function in NPC1 deficient 
cells (Yu et al., 2005). This supports the idea that increased cholesterol storage impairs 
mitochondrial function. Also, another laboratory has reported that Npc1-/- mouse brains 
displayed morphologically abnormal mitochondria containing smaller and more rounded figures, 
with translucent matrices and irregular cisternae. Moreover, the levels of ATP in the brain, 
muscle, and livers of NPC mice were significantly decreased compared with those in WT mice 
(Yu et al., 2005). Investigators concluded that mitochondrial dysfunction and subsequent ATP 
deficiency could be responsible for neuronal impairment in NPC disease (Yu et al., 2005). 
Therefore, I think that the increase in mitochondrial cholesterol content and dysfunction may 
contribute to oxidative damage and warrants further exploration. 
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A related, unresolved and important issue is the intracellular site of action of cystatin B. 
In chapter 2, I demonstrated that cystatin B protects Purkinje cells from cell death induced by 
oxidative stress and cytosolic cathepsins. To inhibit cytosolic cathepsins, cystatin B should be 
localized in cytosol. However, results of a recent study showed that enhanced lysosomal 
cathepsin activity by cystatin B deletion ameliorated Alzheimer’s disease (Yang et al., 2011). 
This study indicated that cystatin B was located at least partly in lysosomal compartments as 
well as in cytoplasm (Yang et al., 2011). Previous studies have yielded mixed results regarding 
the subcellular location of cystatin B to the nucleus, cytosol, and punctate structures within the 
cytoplasm. These conflicting results may be attributable to the different cell types and antibodies 
used for analysis. Cystatin B was distributed diffusely throughout the cytoplasm in an embryonic 
liver cell line and an invasive hepatoma cell line, as detected by staining using a monoclonal 
antibody (Calkins et al., 1998). Another laboratory reported that cystatin B was found mainly in 
the nucleus of proliferating cells, and in both the nucleus and the cytoplasm of differentiated 
cells in nerve growth factor (NGF)-containing media (Riccio et al., 2001). Cystatin B was not 
only localized in the nucleus and the cytoplasm but also colocalized in lysosomes in COS-1 cells, 
and human primary myoblasts (Alakurtti et al., 2005). This study showed that differentiated 
myotubes contained cystatin B localized diffusely in the cytoplasm, but excluded it from the 
nucleus and lysosomes (Alakurtti et al., 2005). Due to a lack of ER signal sequence in cystatin B, 
cystatin B may be attached to the cytoplasmic side of the lysosomal membrane rather than within 
the lysosome. Also, cystatin B is localized in the nucleus of neural stem cells and neurons but in 
the cytoplasm of astrocytes and in lysosomes of glial cells (Brannvall et al., 2003). These 
different localizations of cystatin B may suggest other cellular functions for cystatin B, not only 
cathepsin inhibition but also involvement in apoptosis or transcriptional regulation. 
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4.2 Therapeutic strategies 
In chapter 2, I demonstrated that leaked cathepsins trigger neuronal cell death in NPC 
mice. This work suggested that stabilizing lysosomes or inhibiting cytosolic cathepsins might 
work as a therapeutic approach. In fact, the approach involving lysosome stabilization is being 
tested in NPC disease using recombinant heat shock protein 70 (rHSP70). Prior studies have 
shown that HSP70 binds to the endolysosomal anionic phospholipid 
bis(monoacylglycero)phosphate (BMP), an essential co-factor for lysosomal sphingomyelin 
metabolism, leading to enhanced acid sphinogomyelinase (ASM) activity and stabilization of the 
lysosomal membrane (Kirkegaard et al., 2010). In an NPA model, which is deficient in ASM, 
rHsp70 enhances ASM activity, stabilizes lysosomes and reverts the lysosomal pathology of 
NPA fibroblasts (Kirkegaard et al., 2010). Orphazyme, a small biotech company in Europe, is 
applying these findings to an NPC model and attempting to develop treatments for NPC disease 
based on this strategy (http://www.niemann-pick.org.uk/orphazyme-phase-1-rhhsp70-for-npc). 
The company suggests that rHSP70 may correct conditions of lysosomal functional deficiency 
and concurrent cellular stress. However, I think that it is also possible that rHSP70 may stabilize 
lysosomes and ameliorate cell death by reducing LMP rather than cellular stress. This idea is 
based on a study showing that HSP70 promotes cell survival by preventing the release of 
lysosomal enzymes into cytosol as a result of LMP (Nylandsted et al., 2004). 
I inhibited cytosolic cathepsin activity in NPC patient fibroblasts using genetic and small 
molecule approaches. In the genetic approach, NPC1-deficient fibroblasts were transfected to 
overexpress cystatin B, an endogenous inhibitor. In the small molecule approach, I used CA-
074ME, a specific inhibitor of cathepsin B. Both approaches significantly increased cell viability 
in NPC1 patient fibroblasts damaged by oxidative stress.  
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An important future direction will be to test this approach in a mouse model. CA-074ME 
exhibits membrane permeability, but does not cross the blood brain barrier. In prior studies, it 
was administered intracerebroventricularly in mouse models of traumatic brain injury and 
Alzheimer’s disease, reducing cathepsin B activity (Hook et al., 2007; Luo et al., 2010). Another 
candidate small molecule is E64d, which was derived from E64 (1-[L-N-(trans-
epoxysuccinyl)leucyl] amino- 4-guanidinobutane), isolated from Aspergillus japonicas (Hanada 
et al., 1978). It is an irreversible inhibitor of cathepsin B, other cysteine peptidases, and calpain 
(McGowan et al., 1989). Although it is a non-selective cysteine protease inhibitor, orally 
administered E64d has been shown to be efficacious in animal models. An oral E64d dose is 
hydrolyzed in the gut to the acid form of E64c, which systemically circulates in the biologically 
active inhibitor form (Hook et al., 2015). In previous studies, administration of E64d by oral 
gavage to guinea pigs (1–10 mg/kg/day, 7 days) and feeding E64d (10 mg/kg/day, 2 months) in 
chow resulted in dose-dependent reductions in brain cathepsin B activity and Aβ deposition 
(Hook et al., 2011). Moreover, administration of E64d intraperitoneally inhibited brain cathepsin 
B activity in ischemic rats (5 mg/kg) (Tsubokawa et al., 2006) and epileptic rats (4 μg dose) (Ni 
et al., 2013), indicating that this might be an interesting molecule to test in NPC mice. Additional 
small molecules that inhibit cathepsins have been developed for the treatment of osteoporosis, 
cancer, traumatic brain injury, and Alzheimer’s disease (Siklos et al., 2015) . These drugs may 
have different selectivity, activity, and toxicity. A comprehensive understanding of these 
inhibitors would be of great value in directing therapies for NPC disease in the future. 
 
4.3 Identification of genes that modify neuronal survival and death in NPC1 deficiency 
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In chapter 3, we identified candidate modifier genes, analyzing gene expression patterns 
in the cerebellum using bioinformatics tools. This strategy was based on the phenotype exhibited 
by many models of cerebellar neurodegenerative diseases, including NPC, which show selective 
Purkinje cell vulnerability in anterior lobules. Of 16 genes identified through this approach, I 
demonstrated that one potential neuroprotective gene, HSPB1, promotes survival in NPC cell 
culture models through the inhibition of apoptosis. In addition, I showed that the neuroprotective 
effects of HSPB1 in NPC cell models are mediated by the phosphorylated species. I proposed 
that PKC might be a kinase that phosphorylates HSPB1 in Purkinje cells. This is indirectly 
supported by data showing that phospho-HSPB1 was observed in the cerebellar posterior 
lobules, similar to the expression pattern of PKC Consistent with this model, several studies 
have reported that PKCphosphorylates HSPB1 (Gaestel et al., 1991; Lee et al., 2005; Maizels 
et al., 1998). These results raise several new questions: Is PKCthe major kinase that targets 
HSPB1 in Purkinje cells? What is the upstream signaling pathway that regulates activity of 
HSPB1 and PKC? And, does phospho-HSPB1 have another function in NPC disease? 
To answer the first question, I checked previous studies of HSPB1 kinases and compared 
their expression patterns in the Allen Brain Atlas. I initially examined the expression pattern of 
protein kinase D (PKD). Published studies indicated that phosphorylation of HSPB1 by PKD 
mediates neuroprotection from ischemic neuronal injury (Stetler et al., 2012). This fits with my 
findings. However, according to information in the Allen Brain Atlas, PKD1, PKD2, and PKD3 
are not expressed in cerebellum. Next, several studies reported that mitogen-activated protein 
kinase-activated protein kinase-2 and 3 (MAPKAPK2/3) bind to and phosphorylate HSPB1, 
leading to resistance against oxidative stress (Clifton et al., 1996; Rogalla et al., 1999). 
According to information in the database, MAPKAPK2 is expressed in all Purkinje cells, while 
94 
  
MAPKAPK3 is not expressed at all. Other studies have demonstrated that HSPB1 is 
phosphorylated by p38 mitogen-activated protein kinase (p38 MAPK), which is activated by 
tumor necrosis factor (TNF) (Garrido, 2002; Salinthone et al., 2008). I verified that p38 MAPK 
is expressed in all Purkinje cells. The mismatch of HSPB1 phosphorylation and kinase 
expression patterns — except for the case of PKC — supports my hypothesis that PKC may be 
an important kinase of HSPB1 in Purkinje cells in NPC disease. To confirm this idea, future 
studies could use viral vectors to knock down or over-express PKC in the NPC mouse 
cerebellum, and then look for alterations in Purkinje cell survival. 
The answer to the second question is suggested by previous research and a candidate 
gene from our expression analysis. Prior studies demonstrate that PKC is activated by 
diacylglycerol (DAG) and phosphatidylserine (Griner and Kazanietz, 2007; Stahelin et al., 
2005). To generate DAG, phosphatidylinositol-specific phospholipase C (PLC) hydrolyzes 
membrane phosphatidylinositol-4, 5-bisphosphate into inositol-1, 4, 5-trisphosphate (IP3) and 
DAG (Litosch, 2015). Interestingly, phosphatidylinositol-specific phospholipase C, X domain 
containing 2 (PLCXD2) was identified through our expression analysis (Table 3.1). This gene is 
highly expressed in Purkinje cells in posterior lobules, similar to HSPB1 and PKC This 
observation suggests the expression of regulatory pathway encompassing PLCXD2, PKCand 
HSPB1 which increases Purkinje cell survival in posterior cerebellar lobules.  
The last question raised by my data is whether phospho-HSPB1 has another function in 
NPC disease. I attempted to gain insight into this question by looking at previously published 
studies. Phosphorylated HSPB1 forms dimers and tetramers, while dephosphorylated HSPB1 
forms multimers of up to 800 kDa. Large complexes of dephosphorylated HSPB1 have 
chaperone activity (Ehrnsperger et al., 2000; Jakob et al., 1993) and prevent oxidative damage 
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(Preville et al., 1999). In contrast, smaller, phosphorylated species stabilize the actin 
cytoskeleton and inhibit apoptosis at multiple levels (Charette and Landry, 2000; Huot et al., 
1996; Lavoie et al., 1995; Paul et al., 2010). Because only phosphorylated HSPB1 protected 
NPC neurons in my study, HSPB1 chaperone or anti-oxidative activities are less likely to be 
involved in neuroprotection. Additionally, the level of ubiquitinated protein was unchanged in 
HSPB1 mice that were deficient in Npc1 only in Purkinje cells (Figure 3.6). Other possible 
mechanisms by which HSPB1 might increase neuronal survival in NPC1 deficiency is through 
regulation of key signaling pathways or by influencing lysosomal membrane stability. Prior 
studies reported that the apoptosome, which is a complex of Apaf-1 and cytochrome c, triggers 
LMP (Gyrd-Hansen et al., 2006; Huai et al., 2013). Since HSPB1 sequesters cytochrome c by 
interaction (Bruey et al., 2000), it possible that it could increase lysosomal membrane stability as 
well as reduce apoptosis by decreasing formation of the apoptosome. 
My study confirmed that HSPB1 protects Purkinje cells in an NPC mouse model using 
both overexpression and knockdown approaches. These data are encouraging and prompt me to 
suggest investigating this approach in animal models using small molecules. One of the small 
molecules proven effective at inducing HSPB1 in a rat model is herbimycin A. This small 
molecule increased arterial HSPB1 (Connolly et al., 2003). It is not yet known whether this small 
molecule crosses the blood-brain barrier. Another small molecule of interest is 17-allylamino-17-
demethoxygeldanamycin (17-AAG). This small molecule is under investigation study for the 
treatment of several cancers as an HSP90 inhibitor. Because inhibition of HSP90 induces 
HSPB1, this small molecule can be used as an HSPB1 inducer. Also, it crosses the blood-brain 
barrier and displays no neuronal toxicity in vivo (Egorin et al., 2001; Waza et al., 2005). Because 
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of these advantages, this small molecule is an attractive candidate for preclinical trials in NPC 
animal models. 
 
4.4 Concluding remarks 
Niemann-Pick type C disease is an autosomal recessive lipid storage disorder. Patients 
develop a clinically heterogeneous phenotype that typically includes childhood onset 
neurodegeneration and early death. As yet, there is no effective treatment. I believe that an 
improved understanding of the pathways leading to neurodegeneration in NPC disease will 
enable us to uncover more effective therapeutic targets. In my thesis, I have helped define a 
pathway leading to neuron death, yielding targets for a novel therapeutic approach to NPC 
disease. Further, I have identified several modifier genes that promote neuronal survival in NPC 
disease. I hope the work described in this thesis contributes to a more comprehensive 
understanding of neurodegenerative mechanisms and contributes to the discovery of effective 
treatments for NPC patients. 
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